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ABSTRACT 
NABARUN DASGUPTA: Opioid Analgesic Prescribing and Overdose Mortality in North 
Carolina 
(Under the direction of Steve Marshall) 
 
 Mortality from drug overdose has risen since the 1990s. Composite International 
Classification of Disease (ICD-10) overdose definitions in state vital statistics 
surveillance may include deaths that do not involve controlled substances while missing 
deaths that do. We evaluated seven ICD-10-based definitions using North Carolina 
mortality data from 2008 through 2011. Overdose deaths varied by definition, ranging 
from 734 to 1,202 per year. Up to 16.1% of deaths using the national definition showed 
no evidence of controlled substance involvement, however, additional deaths involving 
controlled substances were not identified. We propose a definition that includes deaths 
from substance use disorders, but removes deaths from pharmaceutical adverse events, 
resulting in 1,149 deaths per year from overdoses involving controlled substances.	  
 Strong associations have been observed between amount of opioids dispensed 
and overdose mortality. Yet, clinical trials consistently show safety of opioid analgesics 
at high doses. To explore this paradox we conducted a prospective cohort study among 
North Carolina residents in 2010 to quantify dose-dependent overdose risk in routine 
clinical practice. Dispensing data were matched to overdose deaths identified in medical 
examiner records. Incidence rates were estimated using regression models. 
Exposure of 1,133,957 person-years to opioid analgesics was observed, corresponding 
to 22.8% of residents. Incidence rates appeared to increase gradually at lower doses, 
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but stayed elevated beyond 200 mg average daily milligrams of morphine equivalents. 
The dose-dependent effect was exacerbated by co-prescribed central nervous system 
(CNS) depressants; rates were ten times higher among opioid analgesic patients 
receiving benzodiazepines. Since 80% of patients were co-prescribed benzodiazepines, 
high dose opioid analgesic use during routine clinical practice was more risky than 
observed in trials that exclude patients receiving other CNS depressants. Exploring 
formulation impacts, incidence rates were ten times greater among those receiving 
combinations of extended-release (ER) and immediate-release (IR) opioid analgesics 
compared to those receiving only IR. At higher doses, for every 1,300 patients treated 
for a year with ER instead of IR, there would be one additional overdose death. As a 
society we urgently need to understand what level of prescribing would strike the correct 
balance between access to care concerns and inadequately trained physicians.  
iv	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CHAPTER 1 
INTRODUCTION 
Overview 
 Non-medical use and misuse of prescription drugs are large and growing public 
health problems in the United States. Deaths from drug overdoses now account for more 
fatalities than motor vehicle-related deaths in the US [1]. The majority (65% nationally) of 
drug overdose deaths involve prescription opioid pain medications [2]. These fatalities 
are a result of both patients using the drugs for pain relief and those using the drugs 
primarily for euphorogenic effects. 
 Quantifying opioid-related overdose morbidity and mortality has been a persistent 
public health challenge. Over the last decade, vital statistics data collection systems 
have adopted the use of International Classification of Disease (ICD) codes to classify 
events. State-based vital statistics rely on composite ICD-based definitions of “overdose” 
that may include deaths that do not involve controlled substances, and may also be 
missing deaths that do involve controlled substances. For example, the main national 
ICD-based definition includes deaths resulting from “poisoning” by controlled 
substances, as well as deaths due to unintended adverse drug reactions from non-
controlled substances, while ignoring deaths from substance abuse. While seemingly 
illogical, the origins lie in the idiosyncratic and historical conventions of ICD. Recent 
guidelines to aid the uniform identification of drug-related morbidity and mortality have 
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been issued by the Injury Surveillance Workgroup 7 (ISW) [3], but have not been 
evaluated. The sensitivity and specificity of the various ICD-based definitions of 
“overdose” is currently unknown.  
 At the national level, a linear ecological association has been observed between 
the total amount of opioids dispensed and parallel overdose morbidity and mortality, 
going back 15 years. This association has been observed at the national, state, and 
county level [4,5,6,7,8,9,10,11,12]. This has led to the general belief that opioids are 
overprescribed. However few studies have documented the association at the level of 
the individual patient [13,14,15,16,17]. Yet, clinical trials and their meta-analyses 
consistently show safety of opioid analgesics at high doses [18,19,20,21,22,23]. 
Additionally, there are concerns that many individuals in chronic pain in the United 
States do not receive adequate analgesic relief, and there is limited safety data on 
overdose risk at higher doses (e.g., over 150 mg per day) that are commonly prescribed 
to chronic pain patients in clinical practice. The ecological studies conducted to date 
have provided limited information relevant to current clinical practices.  Among high-dose 
opioid analgesics, there are clinical choices between immediate-release (IR) 
formulations dosed every four to six hours, and extended-release (ER) formulations 
dosed once or twice per day. There is vigorous debate in the policy realm about the 
relative safety of these two types of formulations.  
 Thus, there is a pressing need to more clearly quantify the dose-dependent 
association between opioid analgesic utilization and overdose risk at the individual level. 
We hypothesized that ER opioids would be associated with greater overdose mortality 
than IR opioids, including at higher doses. We based this hypothesis on ecological 
studies that suggested a linear association between amount of opioid analgesics 
dispensed and overdose mortality at the population level, and the fact that ER opioids 
have more milligrams of active ingredient per unit than IR opioids.  However, in order to 
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evaluate this hypothesis, we need to evaluate and compare the various definitions of 
opioid-related mortality.   
 
Specific Aims 
Aim 1. Evaluate definitions of opioid-related mortality for internal consistency. 
 
Aim 1 Scope: Use decedent-level characteristics to evaluate differences between seven 
ICD-10-based definitions of opioid overdose mortality from North Carolina vital statistics. 
Evaluate the impact of including substance use disorders and pharmaceutical adverse 
events codes in definitions of overdose. Propose a definition for use in surveillance 
based on the findings. 
 
Aim 2. Quantify the association between high-dose opioid analgesic utilization and 
opioid-related mortality. 
 
Aim 2 Scope:  Conduct a prospective cohort study using mortality data linked to opioid 
analgesic dispensing data to examine the association between dose and overdose risk. 
Describe patterns of clinical opioid analgesic utilization, focusing on prescribers, 
prescriptions, and patients, with attention to opioid substance and formulation type. 
Examine the relationship between high dose opioid analgesic prescribing and overdose 
mortality, evaluate the findings of the most similar published study [17], and assess the 
influence of benzodiazepine co-prescribing on dose-dependent overdose mortality. 
Evaluate possible differences between high doses of IR and ER opioid analgesics on 
overdose mortality.
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CHAPTER 2 
BACKGROUND 
Overview 
 This section reviews the epidemiological, clinical and pharmacological knowledge 
base relevant to pain management and overdose. It includes a literature review on 
published individual-level studies of opioid analgesic dose and overdose death. 
 
 
International Context 
 
 The use of opioids in the management of pain has long been tempered with 
concerns about abuse, addiction, and diversion of medicinal supplies into illicit channels 
of trade. The World Health Organization designates four opioids (morphine, codeine, 
methadone, buprenorphine) used to treat pain and addiction on the Model List of 
Essential Medicines [24]. The cultivation, manufacture, distribution, and dispensing of 
opioids are subject to international control, with the intent of assuring access for 
legitimate medical and scientific purposes while minimizing diversion and abuse [25]. 
These international obligations continue to influence national control programs.  
There are significant differences among nations both with respect to utilization of 
controlled substances and the degree of concern over diversion of such drugs to 
unsanctioned use [26]. The United States and Canada have the highest per capita 
consumption of opioids in the world, according to the annual Report of the International 
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Narcotics Control Board (INCB), the United Nations body responsible for 
monitoring and enforcing the treaties that apply to the international manufacture, sale 
and distribution ofcontrolled substances [25]. These countries also have high levels of 
public concern with the non-medical use and abuse of prescription and illicit drugs. The 
public health problem created by the inappropriate use of opioids is pervasive in both 
countries. 
 
Drug-related Mortality in the United States 
 In the United States, rates of mortality attributable to unintentional drug poisoning 
have risen consistently since the early 1990s [27]. In 2009, the national age-adjusted 
death rate from drug poisonings was 12.0 per 100,000, making it the leading cause of 
injury death surpassing motor vehicle-related injuries [28] (Figure 2.1). Overdose is the 
leading cause of death among young injection drug users in the United States [29] and 
outpaces mortality from injection-borne infectious diseases [1]. By way of comparison, in 
2008 the age-adjusted mortality rates per 100,000 were 2.5 for viral hepatitis and 3.1 for 
HIV/AIDS [1].  
 The Centers for Disease Control and Prevention (CDC) report that “in 2007, 
approximately 27,000 unintentional drug overdose deaths occurred in the United States, 
one death every 19 minutes” [27]. In 2008, prescription opioid analgesics were involved 
in 73.8% of drug overdose deaths, meaning they were more frequently involved than 
heroin, cocaine and methamphetamine combined. The pharmaceutical opioids most 
often causally identified in post-mortem toxicology reports are fentanyl, hydrocodone, 
methadone, morphine, oxycodone and oxymorphone [6,27]. 
 The amount of opioids prescribed in the United States has risen substantially 
over the past decade, leading many to propose that a linear correlation exists between 
the amount of opioids dispensed and the unintended negative consequences associated 
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with these medicines (Figure 2.2). This observed association suggests that opioid 
analgesics are “overprescribed” for post-operative and other types of pain [30]. 
 It is clear that, among the pool of decedents, there are heterogeneous reasons 
for ingesting prescription opioids. Deaths occur in pain patients who mistakenly take 
more pain relievers than directed by clinicians (misuse), as well as individuals using 
diverted opioids for euphoric effect, e.g., to get high. The percent of overdose decedents 
who had a prescription for the opioid involved in their overdose fatality is in the range of 
44% to 91%, varying by state and definition [9,31,32,33,34], suggesting that substantial 
portions of those dying from an overdose are being exposed to pharmaceutical opioids 
outside of medical supervision. In contrast to mortality, in a national survey of young 
adults who endorsed nonmedical use of prescription analgesics, 53% reported they 
received them free from a relative or friend [35]. However, the median age of overdose 
death in the United States is around 40 years [36], while the peak in nonmedical use is 
in the 20s, suggesting that opioid use is causal but not sufficient to result in overdose 
death. Regardless of the reasons for ingestion of an opioid analgesic (e.g., pain, 
addiction, etc.), there are multiple factors that influence whether the exposure will result 
in an overdose, and others that influence whether the overdose will be fatal. 
 
Pain and Public Health 
 The belief in the causal connection represented by the linear association between 
opioid prescribing and overdose (Figure 2.2) is at the heart of much of the policy 
response.  The assumption that reducing the amount of opioid analgesics prescribed will 
result in fewer overdose deaths, although logical, has been subject to limited empirical 
investigation.  
 In pharmacoepidemiology, the underlying prevalence of disease that a medicine is 
intended to treat can be used as a rough measure to address whether a drug is 
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prescribed at appropriate levels in the population. However, there are substantial 
limitations in estimating national pain prevalence, let alone the prevalence of painful 
conditions that would be responsive to opioid therapy. Pain is by its very nature 
subjective, and no biometric test can accurately predict the amount of pain an individual 
is in. Definitions of pain in the major federally sponsored self-report surveys (e.g., 
National Health and Nutrition Examination Survey [NHANES]) vary greatly, do not 
distinguish acute from chronic pain, do not attempt to link pain to specific medical 
conditions, and often exclude children and institutionalized populations. 
 In one of the few population-based estimates of its kind, the CDC reports that 30% 
of Americans ages 45-64 reported problems with pain lasting more than 24 hours in the 
previous month [37]. It remains an open question how many of these individuals would 
benefit from opioid pharmacotherapy for chronic pain. Other CDC data suggest that the 
most common causes of pain in the last three months are musculoskeletal injuries, with 
lower back pain being the most common (Figure 2.3). There is relatively little debate on 
the appropriateness of using opioids in cancer pain, although what constitutes “cancer 
pain” can depend on the perception of the physician. However, despite the prevalence of 
musculoskeletal pain, and a plethora of clinical trials showing efficacy, the use of opioid 
analgesics in chronic non-cancer pain has recently been a highly contested area of 
clinical and policy debate focused on the Food and Drug Administration (FDA) [38,39]. 
 In a recent report, Relieving Pain in America, the Institute of Medicine attributes 
the observed rise of the prevalence of chronic pain conditions to greater expectations for 
pain relief among patients, degenerative musculoskeletal disorders of an aging 
population, obesity, increased survivorship after traumatic injury and cancer, and 
increases in the number and complexity of surgical procedures [40]. Studies of pain in 
nursing homes and among war veterans consistently reveal that they receive inadequate 
pain treatment; even if the patients are receiving opioids, the dose may not be sufficient 
	   8	  
to address pain needs [41,42,43]. Paradoxically, pain appears to be under-treated in the 
United States in some populations, and yet there is a belief that opioids are 
overprescribed with resulting unacceptable levels of overdose. The continued outpatient 
use of opioid analgesics is contingent upon our ability to address the health and societal 
concerns associated with broader availability of these essential medicines.  
 
Opioid Pharmacology and Pain Management 
 Clinical practice differentiates between three main types of pain frequency: acute, 
chronic and breakthrough [44]. Acute pain usually arises from minor physical injuries, 
limited surgical procedures, headaches, etc. The pain is intermittent and resolves in less 
than a month. Chronic pain (or “persistent pain”) can arise from more serious injuries 
and invasive surgical procedures, cancer, and degenerative nerve and musculoskeletal 
diseases (e.g., fibromyalgia, lupus, etc.), often with genetic underpinnings. The pain 
lasts more than a month. Breakthrough pain is a phenomenon that routinely occurs in 
patients whose pain is otherwise well-controlled (using opioid analgesics or other 
pharmacotherapies). In these instances, a sharp and temporary pain may manifest itself 
and require additional pain medication. 
 Another dimension of pain is its intensity. Mild pain usually does not require opioid 
pharmacotherapy, and can be controlled with over-the-counter medications, non-opioid 
prescription drugs, and physical manipulation (e.g., massage), and often self-resolves 
without intervention. When pain results in interference with daily functioning and sleep, it 
is classified as moderate-to-severe, although in practice the differentiation between 
moderate and severe is often subjective. 
 The active opioid substance in modern analgesics in the United States can be 
classified broadly into opioids that are: (1) full mu-opioid receptor agonists (fentanyl, 
hydrocodone, hydromorphone, methadone, morphine, oxycodone, and oxymorphone), 
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and (2) those that have partial effect at the mu-opioid receptor and may also have action 
in other neurophysiolgical pathways that modulate the perception of pain (e.g., 
serotonin, γ-Aminobutyric acid [GABA], etc.). The latter have less risk for respiratory 
depression due to the lower levels of central nervous system depression (tramadol, 
propoxyphene, buprenorphine, with codeine and meperidine of intermediate risk). Other 
opioid formulations are used in modern medicine to suppress cough, usually found as 
syrups and primarily containing codeine (also hydrocodone), but are rarely implicated in 
overdose deaths. In addition to lower potency of the active ingredient, these liquid 
formulations contain excipients that make it difficult to consume large quantities, and are 
therefore placed in a lower controlled substance schedule. We do not include these in 
the definition of “opioid analgesics,” a distinction from many other studies. This 
distinction becomes relevant when we analyze the association between opioid 
analgesics and overdose mortality in Aim 2. 
 In general, opioids increase activity at one or more G-protein–coupled 
transmembrane molecules, known as the µ-, δ-, and κ-opioid receptors. These receptors 
are activated by both endogenous opioid peptides and pharmaceutical opioids. 
Endogenous opioids  (endorphins, enkephalins, dynorphins and endomorphins) function 
as hormones and neuroregulators in the limbic system and elsewhere, and are 
responsible for feelings of well-being and analgesia. They also control respiration and 
many other roles that are not fully characterized. The receptors are widely distributed 
throughout the human body; those in the anterior and ventrolateral thalamus, the 
amygdala, and the dorsal-root ganglia mediate nociception. Opioid agonists also bind to 
receptors in the gastrointestinal tract to decrease gut motility (e.g., constipation is a 
common clinical manifestation of long-term opioid pharmacotherapy). Based on 
knockout mouse studies, of the three known opioid receptors, the µ-opioid receptor is 
believed to be responsible for the preponderance of clinical effects of analgesia and 
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manifestations of tolerance [45]. Unlike endogenous opioids that naturally cycle in 
concentration in the extracellular matrix, repeated dosing of pharmaceutical opioids or 
heroin leads to persistent binding and desensitization of these receptors leading to a 
state of tolerance whereby more of the opioid must be administered over time to achieve 
the same clinical effects. Thus, when exogenous opioids are abruptly discontinued, 
resensitization of these receptors leads to symptoms of opioid withdrawal (e.g., agitation, 
anxiety, diarrhea, muscle aches, insomnia, vomiting, etc.) [46]. 
 There are more than a dozen alkaloids that naturally occur in the plant Papaver 
somniferum (somniferum means to cause sleep in Latin). Of these, morphine, codeine 
and thebaine are the most plentiful, and these molecules can be modified to produce 
drugs that have varying degrees of biological effects. Modifications of moieties give rise 
to differing side effect profiles (e.g., more potent opioids cause less constipation, 
oxymorphone is associated with less itching than codeine, etc.), while maintaining 
structural similarity. Because of the differences in potencies between opioids, clinicians 
refer to equianalgesic conversion tables when switching patients from one opioid to 
another during opioid rotation. Clinically, opioid rotation can assist in improving side 
effect profiles and reducing tolerance for patients maintained on chronic mono-opioid 
therapy. While these are rough guidelines for clinical conversion, the tables can be used 
in epidemiologic research to standardize by potency when analyzing utilization data. 
Morphine is the archetypical molecule and data are often presented in terms of 
“milligrams of morphine equivalents” (MME). 
 Among the pharmaceutical opioid formulations available in the United States there 
is a broad distinction between short-acting (“immediate release” [IR]) opioid formulations 
and long-acting (“controlled-release” or “extended-release” [ER]) analgesics. IR opioids 
are intended for use in acute pain, and often come combined with acetaminophen or 
ibuprofen. Common branded IR opioids contain oxycodone (Percocet, Tylox, etc.), 
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hydrocodone (Vicodin, Lortab, Lorcet, etc.), hydromorphone (Dilaudid), and 
oxymorphone (Opana). ER formulations have labeled indications of moderate-to-severe 
pain where around-the-clock analgesia is required. These drugs are found as tablets or 
capsules with slow-release mechanisms and transdermal patches that regulate the 
elution of opioid over 12 or 24 hours. Some branded ER opioids are: fentanyl (Duragesic 
patch), hydromorphone (Exalgo), morphine (MS Contin, Kadian, Avinza, Embeda), 
oxycodone (OxyContin), oxymorphone (Opana ER), tramadol (Ultram ER). Methadone is 
also prescribed as a solid oral tablet for chronic pain management. Since the plasma 
half-life of methadone is sufficiently long enough to allow for chronic pain control with 
single doses (e.g., without a pharmaceutically engineered extended-release 
mechanism), it is considered a “long-acting” (LA) opioid, but is often classified alongside 
ER opioids, as we have done in our research. The IR opioids have one recognized sub-
category, called “ultra rapid release” that have fentanyl as an active ingredient. Fentanyl 
is a potent synthetic opioid that has quick onset, a short duration of action, and moderate 
affinity for the µ-opioid receptor. These products are used for sudden debilitating spikes 
in pain intensity lasting less than an hour, known as breakthrough pain (“flare ups”), for 
patients whose pain is being controlled with around-the-clock analgesic(s). These 
products come in different formulations: oral lozenge (Fentora), on a stick as “lollipops” 
(Actiq), nasal spray (Lazanda), buccal soluble film (Onsolis), and sublingual tablet 
(Abstral). These products have labeled indications only for cancer pain, but are widely 
used for non-cancer pain. In general, they are expensive products and used much less 
frequently than other IR opioids for breakthrough pain. 
 The advent of ER opioids in the United States can be traced back to the mid-
1980s. While long-acting methadone had been available earlier, the launch of MS Contin 
(extended-release morphine; Purdue Pharma, Stamford, Connecticut, United States) 
was the first extended-release opioid product engineered to slowly release a short-acting 
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opioid during the transit of the tablet through the gut, and allowed for a single tablet to be 
taken every 12 hours. The other IR opioid formulations on the market at the time 
required dosing every four to six hours. The ER formulation was lauded by pain patient 
advocates for allowing patients to receive adequate analgesia to sleep through the night 
or work through the day, without having interruptions for additional dosing. The 
pharmacokinetic benefit is that the plasma concentration of the opioid remains at a 
steady state during the 12 or 24 hour dosing period; using the same amount of IR opioid 
would result in “peaks and valleys” in plasma concentration with corresponding 
vacillations in pain relief. The justification for extended-release opioid preparations is that 
a steady, continuous release of the opioid over 12 or 24 hours would lead to better 
control of chronic pain because of a smaller mean difference in plasma concentration 
between Cmax and Cmin, while maintaining the same area under the curve (AUC).  
 In addition to steady state plasma concentration, the other oft-cited benefit of ER 
opioids is that they do not contain acetaminophen, ibuprofen or naproxen. Many 
immediate-release opioid pain relievers contain ibuprofen (200mg to 400mg) or 
acetaminophen (325mg to 750mg) in addition to codeine, hydrocodone, oxycodone, 
propoxyphene, or tramadol. Some brand names of combination products are Ultracet, 
Vicodin, Percocet, Tylox, and Lortab. However, long-term ingestion of ibuprofen and 
acetaminophen is associated with kidney failure and hepatic injury, respectively [47]. 
This is one of the justifications for using extended-release opioids for chronic pain since 
they do not contain either ibuprofen or acetaminophen [48,49]. FDA-approved labels for 
non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen-containing 
analgesics note that taking these for more than a couple of weeks can lead to liver, 
kidney and gastrointestinal tract damage. In addition to long-term risks with 
acetaminophen, there is also concern about patients receiving high doses of 
acetaminophen even over short periods of time. In recognition of the risk of hepatic 
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injury, the FDA limited the amount of acetaminophen in opioid analgesic combination 
products to 325mg on January 13, 2011. The labeled upper limit of daily acetaminophen 
dosing is 4 grams when taken as an immediate-release combination opioid pain reliever. 
However, due to concerns about overdose risks with extended-release opioids, there is 
a belief in the pain management community that high doses of combination opioids are 
being unjustifiably prescribed to patients, partially out of fear of abuse and overdose 
associated with ER opioids. Therefore, we will examine high-dose and long-term IR 
opioid analgesic utilization in Aim 2. 
 While the clinical upside to ER opioids for chronic pain management has been 
important in hospice and palliative care, the amount of opioid in each ER tablet, capsule 
or patch is generally significantly more than in IR formulations. The ER formulations may 
be more attractive outside the medical realm to those seeking to obtain a larger bolus of 
opioid for their euphorogenic effect, i.e., to get high. The higher mass of opioid also may 
increase the overdose risk of ER medications over IR medications when taken other 
than as indicated, when taken without proper clinical monitoring, or when tampered with 
(e.g., crushed to snort or inject) to intentionally release all the active ingredient at once. 
 
Clinical Practice of Pain Management 
 As increasing numbers of patients present with chronic pain complaints, it is 
unavoidable that some will have or have had substance abuse problems. For example, 
the 2010 federally sponsored “household” National Survey on Drug Use and Health 
(NSDUH) reported that 12.2% of males and 5.8% of females aged 18 years and older 
had diagnosable substance dependence or abuse in the past year [50]. While there are 
clinical tools to differentiate the “legitimate patient” from the “drug seeker,” these 
distinctions may be difficult to ascertain in a given individual patient. Furthermore, an 
individual may change their behavior over time. Further complicating medical care is that 
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those with substance abuse and dependence disorders frequently suffer from severe 
pain at higher rates than the general population, thus necessitating strategies for 
addressing both conditions simultaneously [51]. Effective strategies for treating patients 
with substance use disorders (including opioid therapy) have been articulated [52].  
 Primary care physicians prescribe more than 40% of the opioids in outpatient use 
in the United States [53]. ER opioids are prescribed more frequently by anesthesiologists 
and pain medicine and rehabilitation specialties than others. Prior to the early 1990s, 
primary care physicians prescribed a much smaller proportion of opioid analgesics, with 
specialty practices making up the bulk of opioid analgesic prescribing. While increased 
prescribing by primary care doctors has led to wider access to pain treatment, a general 
concern is that non-specialized doctors may not have been adequately trained to 
prescribe these medications safely [53].  At the same time, there are theoretical 
concerns that physicians will stop prescribing opioid analgesics because of the fear of 
overdose, leading to decreased access to pain medication. Therefore, we utilized the 
number of clinicians prescribing opioid analgesics as an important variable in Aim 2. 
 Opioids are the mainstay for the management of moderate to severe chronic and 
acute pain the United States. Assessing the evidence for opioid analgesic effectiveness 
in cancer and non-cancer pain is beyond the scope of this dissertation. A recent review 
article by the American Society of Interventional Pain Physicians (ASIPP) assessed the 
evidence of published and unpublished clinical trials and epidemiologic reports about the 
effectiveness and adverse consequences of opioid therapy [53]. While we have 
summarized key findings above, we refer readers to this resource for a detailed 
description of randomized and observational trials. 
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Etiology of Opioid Overdose 
 At an individual level, the risk factors for fatal accidental overdose among drug 
users and pain patients appear to be due to three major factors: 
• Opioid exposure in individuals with no or inadequate opioid tolerance 
Examples: new pain patients without a previous history of opioid therapy, 
infrequent drug users, unexpected fluctuations in purity of heroin 
• Opioid exposure after disruption of physiological tolerance 
Examples: resumption of previous dose of opioids after taper for surgery 
requiring anesthesia, resumption of previously normal dose after release from 
prison or abstinence-based drug treatment, failure to maintain level of tolerance 
due to the inability to procure opioids 
• Multiple central nervous system depressants 
Examples: combining prescribed opioids and benzodiazepines, drinking alcohol 
in combination with opioids 
 
 Other contributory risk factors for opioid-induced respiratory depression include 
genetic polymorphisms resulting in idiosyncratic opioid metabolism, place-conditioned 
responses, and respiratory, circulatory, and metabolic disorders [54]. More broadly 
construed, deaths involving opioid analgesics result from a combination of physiologic, 
genetic, and behavioral risk factors, compounded by broader social determinants such 
as health literacy, poverty, access to healthcare, and farther upstream, the causes of 
painful conditions such as employment-related injuries, military trauma, motor vehicle 
accidents and malignancies. Structural determinants, such as stable housing availability, 
drug laws, and policing practices also play a role. For example, studies of overdose 
among drug users have documented a “risk environment” that included distrust of 
medical institutions arising from mistreatment, fear of police, armed international 
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conflicts, and perceived ineffectiveness of the emergency response as deterrents to 
seeking medical help in an overdose situation [55,56,57]. Consideration of the risk 
environment includes the interplay of physical, genetic, behavioral, social, economic, 
and policy factors that influence opioid-related morbidity and mortality [58,59]. If 
prevention of opioid analgesic overdose deaths was as simple as reminding people to 
call 911 in an emergency or improving wording on a prescribed medication’s package 
insert, we would have observed a reversal in the mortality trends involving prescription 
opioids long ago. Rather, the rising death toll indicates society’s failure to recognize the 
complexity of prescription opioid abuse and the multiple societal and structural factors 
that contribute to the risk environment and ultimately to overdose mortality.  
 Beyond overdose mortality, there are social and structural determinants that 
influence who receives opioid analgesics in the United States. The relationship between 
poverty, pain and drug abuse is poorly understood. Substance abuse problems and 
poverty have long reinforced each other, at the extreme intertwined with major 
psychiatric disorders and homelessness. Employment opportunities in lower income 
communities are often limited to jobs with considerable physical stress or danger, 
including military positions; the Institute of Medicine reports that a quarter of those below 
100% of the federal poverty level suffer from pain on a regular basis [40]. When 
sustained over years, on-the-job injuries can give rise to chronic painful conditions, 
resulting in a downward spiral of disability and poverty. Opioid analgesics may allow 
those with otherwise debilitating physical injuries to maintain employment, but may also 
put them at risk of experiencing an overdose. While there is consensus that these 
factors may influence overdose risk, the individual level measurement of them is beyond 
the scope of this dissertation analysis. 
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Published studies on opioid analgesic dose and overdose death 
 At the societal level, many studies have suggested a co-linear ecologic 
association between the total amount (by weight or number of prescriptions) of opioids 
dispensed and overdose morbidity and mortality over the last 15 years 
[4,5,6,7,8,9,10,11,12]. Locations with the highest levels of opioid prescribing also have 
the highest rates of overdose deaths involving these substances. Simply summarized: 
the more that opioid analgesics are dispensed, the greater the overdose morbidity and 
mortality involving these substances are observed at the population level. These studies 
universally assume a linear relationship between prescribing and overdose, which may 
or may not be justified. Although there are caveats about inter-level (ecological) bias 
[60], there is a tendency in these papers to draw conclusions about individual-level risk 
of overdose based on opioid exposure.  
 We identified five peer-reviewed published studies that have attempted to 
quantify the individual-level dose response between opioid analgesics and mortality. 
These five studies were identified by tracing references, searches of online databases 
(e.g., PubMed and Web of Science), but also from having followed the literature and 
public debate for the past ten years. We did not make an attempt to identify unpublished 
studies, or to conduct a systematic review or meta-analysis, because that was beyond 
the scope of this dissertation. However, these studies are widely considered to be the 
five most important and recent papers on the topic. The five studies are summarized in 
Table 5.1, and described below.  
• Dunn, 2010:  The earliest and smallest study of note [14] was a cohort study 
among 9,940 members of a health management organization in Washington, 
United States, during a nine-year period ending in 2005. That study was limited 
to patients with chronic non-cancer pain. They observed 51 opioid-related 
overdoses, six of which were fatal.  They reported a HR of 8.9 (95 percent CI: 
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4.0, 19.7; CLR 4.9) comparing those with at least 100 mg average daily MME to 
the lowest strata of 1 to less than 20 mg/day MME. This is the only one of the five 
that includes data on non-fatal overdoses.  
• Bohnert, 2011:  A case-cohort study looked at medical records from a random 
sample of 154,684 nearly all-male military veterans in the United States during a 
four-year period ending in 2008, which reported 750 overdose deaths identified 
through vital statistics [13]. They compared the highest strata, using maximum 
daily dose, of at least 100 mg/day to a reference group of 1 mg/day to less than 
20 mg/day. Their stratified results were HR=12.0 (95 percent CI: 4.4, 32.5; CLR 
4.4) for cancer pain, and HR=7.2 (95 percent CI: 4.8, 10.6; CLR 2.2) for chronic 
non-cancer pain. They did not include transdermal fentanyl in their analysis. 
• Gomes, 2011a:  A nested case-control study [16] in Ontario, Canada included 
607,156 non-malignant pain patients receiving opioid analgesics through a public 
assistance program during a ten-year period ending in 2006, and 498 overdose 
fatalities identified by coroners. They reported an adjusted odds ratio (OR) of 2.9 
(95 percent CI: 1.8, 4.6; CLR 2.5) comparing 200 mg/day or greater to the 
reference dose of 1 to 19 mg/day. They did not include hydrocodone products. 
• Gomes, 2011b: Another investigation conducted in Ontario [15] was a cohort 
study of non-malignant pain patients using records from 154,411 
“socioeconomically disadvantaged” beneficiaries of a government drug 
assistance program. They reported 302 overdose deaths during two years of 
follow-up ending in 2006. They reported an IRR of 2.2 (95% CI: 1.92.5; CLR 1.3) 
for 201 to 399 mg/day, with a reference group of average MME >0 to 20 mg/day. 
They also reported IRR 2.3 (95% CI: 1.7, 3.0; CLR 1.8) for 400 mg/day or 
greater. This is the only study to provide multiple effect estimates for prescribed 
dosages over 100 mg/day. 
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• Paulozzi, 2012:  The study most similar to Aim 2 was conducted [17] as a 
population-based case-control study of 730,381 patients, during an 18-month 
period ending in 2008, which included 300 overdose deaths among residents of 
New Mexico, United States. They reported an OR of 11.3 (95 percent CI: 8.1, 
15.8; CLR 1.9) for those with greater than 120 mg/day average MME, however 
their control group included controls receiving less than 40 mg/day as well as 
controls who had not received any opioids. They included buprenorphine 
products in their exposure, even though these were primarily used for addiction 
treatment and not pain during the study period. 
 
 While it is not surprising to find a dose-dependent association between opioid 
utilization and associated adverse events, these individual-level studies support the 
association observed in ecologic studies. However, important limitations to the clinical 
utility of the evidence base formed by these five studies should be noted.  First and 
foremost, these studies offer limited information on the gradient of risk above 200 mg per 
day of morphine equivalents.  However, there is widespread clinical outpatient use over 
this level. Second, the interpretation of the studies can be difficult if attempting to 
distinguish between safety risks inherent to IR versus ER formulations, since both can 
be used at higher doses. One study reported counts by four specific types of IR and ER 
formulations but not effect measures [15], and one adjusted for formulation in models 
without providing stratified results [16]. The generalizability of four out of the five studies 
is limited due to reimbursement-oriented study settings. The variation between studies in 
patient selection, drugs included, method of identification of overdose, and duration of 
observation also makes it difficult to compare them directly to one another. This 
dissertation sought to address many of these limitations.  
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FIGURES 
 
Figure 2.1. Annual age-adjusted mortality rates per 100,000 for selected diseases, 
United States, 2009. There are more drug overdose deaths (pink) than motor vehicle 
accidents. Drug overdose deaths are a larger cause of death among drug users than 
HIV or viral hepatitis. 
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Figure 2.2. Rates of opioid analgesic overdose death, substance abuse treatment 
admissions, and kilograms sold, United States, 1999 to 2010. There has been a co-
linear increase in the amount of opioid analgesics dispensed and unintended 
consequences of their availability. Source: CDC, Morbidity and Mortality Weekly Report, 
November 4, 2011, 60(43); 1487-1492. 
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Figure 2.3. Age-adjusted proportion of adults reporting pain in the last three 
months, by site of pain, United States, 2009. The most common type of chronic pain 
in the United States is lower back pain. Source: Institute of Medicine, Preface of 
Relieving Pain in America, 2011. 
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CHAPTER 3 
RESEARCH DESIGN AND METHODS 
Overview 
 There are two major types of data used in this analysis, mortality data and 
prescription utilization data. Aim 1 used only mortality data, while Aim 2 will used both 
mortality and prescription utilization data. The goal of Aim 1 was to describe in detail the 
nature of each of seven proposed definitions of overdose and yield a proposed definition 
for use in surveillance, and evaluate the impact of including substance use disorders and 
pharmaceutical adverse events codes in definitions of overdose. The goal of Aim 2 was 
to draw insight from regression models that estimate the association between opioid 
prescribing dose and overdose mortality risk at an individual level. 
 In Aim 1, seven ICD-10 based definitions of “drug poisoning” or “overdose” were 
identified, suggested by ISW and national health authorities in the United States and 
Australia (described in detail in the following chapter). Deaths matching the seven 
definitions were identified from among all deaths in NC vital statistics data. Variations in 
distributions of sociodemographic variables and other drug involvement were explored 
for each of the seven definitions. Population rates were calculated using Poisson 
regression with population denominators from NCHS bridged population estimates. 
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 Deaths that may have been due to pharmaceutical adverse events and 
substance use disorders were identified, and we determined whether these were 
included in each definition. We compared demographic and co-morbidity information 
with known deaths from controlled-substance overdoses to judge whether the definitions 
would benefit from inclusion of these records. Based on these findings, we proposed an 
ICD-based definition of controlled substance overdose that could be used to potentially 
generate more accurate estimates of mortality. 
 An additional analysis, not included as part of the submitted peer-reviewed 
paper, dealt with “narcotic unspecified” deaths. Despite having markedly different 
mechanisms of toxicity, the historical artifact of classifying drugs derived from both the 
opium poppy (Papaver somniferum) and the coca leaf (Erythroxylum spp.) as “narcotics” 
results in a modern day methodological challenge of differentiating deaths involving 
derivatives of these plants, whether medicinal and illicitly manufactured [3,36]. The 
differences in the mechanisms of toxicity between opioids and cocaine, as well as 
separate clinical management, make it important to distinguish between the two in vital 
statistics data. Therefore, we also evaluated the impact of including “narcotic 
unspecified” (T40.6) deaths as suggested by three of the seven definitions. There are 
specific ICD-10 toxicology (T) codes for opium (T40.0), heroin (T40.1), pharmaceutical 
opioids derived from the opium poppy (T40.2), methadone (T40.3), and synthetic opioids 
(T40.4); however, cocaine (T40.5) is also included among the T40 codes. The possibility 
of misclassification arises because deaths involving the catchall “unspecified narcotics” 
(T40.6) could be due to either opioids or cocaine, leading to inconsistency in whether 
T40.6 deaths ought be included in opioid overdose surveillance definitions. The fear is 
that excluding deaths involving T40.6 could lead to an undercount of opioid overdose 
deaths, but that including them may mean cocaine deaths get counted as opioid deaths. 
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 We used data the same data from NC vital statistics and conducted a subset 
analysis of all deaths with a T40.5 code. We examined codes for contributing causes-of-
death to see if we could identify whether the overdose was due to opioids or cocaine, or 
other discernible patterns. We supplemented our findings with a brief examination of the 
literal causes-of-death listed on death certificates as part of ongoing study by the NC 
Division of Public Health. 
 We also assessed whether seasonality was present in NC overdose mortality 
data, in order to determine if this concern would need to be accounted for in modeling 
when we were originally considering time series modeling. This analysis was not 
submitted as part of the peer-reviewed paper. We selected Definitions 1 and 4 to 
represent the broad and more general definitions. Gross time-vary trends were visually 
assessed with the aid of LOESS smoothing. The Walter and Elwood test for seasonality 
was applied [61], with and without adjustment for all other deaths among NC residents. 
This test takes advantage of the coincidence that there are 365 days in a year, and 360 
degrees in a circle. Visually, by aggregating counts by day-of-the-year for multiple years, 
areas of uneven distribution along the perimeter of the circle suggest seasonal trends. 
Statistically, the amplitude of seasonal variation and the date on which the maximum 
occurs are modeled as a simple harmonic function, with a goodness-of-fit test based on 
the chi-squared distribution. Significance was assessed at p=0.10, because the test is 
low power to detect seasonality. We implemented the test using the SEAST module in 
STATA version 12 (College Station, Texas, United States) [62].  
 For Aim 2, we conducted a cohort study of all North Carolina residents 
(n=9,560,234) in 2010, using electronic controlled substances prescription monitoring 
program data. The outcomes were identified using data from an ongoing study of 
overdose mortality conducted by the Division of Public Health. First, we describe 
patterns of clinical opioid analgesic utilization, focusing on prescribers, prescriptions, and 
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patients, with attention to opioid substance and formulation type. Then, we examined the 
relationship between high dose opioid analgesic prescribing and overdose mortality, and 
potentially confirm the findings of the most similar published study [17]. Finally, we 
evaluated possible differences between high doses of IR and ER opioid analgesics on 
overdose mortality.  
Data Sources 
 Three data sources maintained by the North Carolina Division of Public Health 
provided drug-specific information for this study. Vital statistics were used to identify 
overdose decedents and describe demographic characteristics. Medical examiner post-
mortem toxicology data were used to determine what substances were involved in the 
overdose death. Finally, data from the North Carolina Controlled Substances Reporting 
System (CSRS), the state’s prescription monitoring program, were used to gather 
prescription histories for each overdose decedent. These data were combined with 
CSRS data for all NC residents to create an individual-level analysis dataset. Incidence 
rate ratios were calculated using Poisson regression implemented with generalized 
estimating equations. 
 
Mortality Data 
 Mortality data for 2008 through 2010 were obtained from the North Carolina Vital 
Statistics Dataverse at The Howard W. Odum Institute for Social Science of the 
University of North Carolina at Chapel Hill [63]. Vital statistics mortality data for 2011 
were obtained from the Injury and Violence Prevention Branch, North Carolina Division 
of Public Health, Department of Health and Human Services. For the “unspecified 
narcotics” analysis, death certificate listings of the literal text of the cause-of-death fields 
for 2010 and 2011 were retrieved. Files from NC Office of the Chief Medical Examiner 
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were obtained by DPH staff as part of an ongoing collaboration. Information from 
medical examiner files was extracted into a structured database, for the purpose of this 
research. Details on determination of death and data abstraction are presented in the 
methods section of the second paper. 
 
Prescription Data 
 We used data from the state’s Controlled Substances Reporting System (CSRS) 
to construct exposure variables and quantify opioid analgesic dispensing in North 
Carolina. The CSRS is one of a set of clinician-oriented databases generally known as 
prescription monitoring programs (PMP). These state government-run programs are 
centered around electronic databases with the general goal of limiting overdose and illicit 
activities (e.g., diversion of medicines from “legitimate” channels) associated with 
prescription controlled substances. PMPs are funded largely by federal grants through 
the Department of Justice, supplemented with funding from state governments. 
Clinicians can query the database before prescribing a controlled substance to 
determine if the patient has received controlled substances from other healthcare 
providers; law enforcement and medical examiners are allowed access to the database 
when they are investigating specific cases. The CSRS was approved by the General 
Assembly in August 2005 and became operational on July 1, 2007. Data are generated 
when a prescription for a controlled substance is dispensed at regulated pharmacies in 
North Carolina. The data that are captured basically include each field of information 
legally required to be on a North Carolina prescription for a controlled substance. The 
data are stored locally at the pharmacy and transmitted periodically (within two weeks) to 
a central database owned by the NC Division of Mental Health, Developmental 
Disabilities and Substance Abuse Services (DMHDDSAS). We obtained de-identified 
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data with permission from the Division of Public Health for all prescriptions dispensed 
from 2009 through 2011.   
 Converting prescription-level data to a person-level analysis dataset required 
extensive formatting. The starting dataset was 7.1 gigabytes in size, with 54,825,930 
observations. Data cleaning steps are described below, and represented in Figure 3.1. 
• 964,678 observations were deleted because county of residence was not a NC 
county, resulting in 53,861,252. 
• In order to eliminate non-controlled substances from the dataset, we decided to 
manually classify the top 400 named drugs by the number of prescriptions by 
listing their active ingredient and therapeutic class. This represents 54,757,801 
prescriptions from the original dataset, or 99.931% of all the prescriptions. The 
top 400 drugs in the CSRS dataset included all the major drugs of interest; the 
top 175 are used by state health department officials to roughly clean the data, 
however, we wanted greater confidence for individual-level modeling. We were 
able to include any dispensed controlled substance that had more than five 
prescriptions per month on average in the whole state. 62,975 observations were 
deleted because they were neither a controlled substance nor in the top 400, 
resulting in 53,731,213 observations. 
• Days supply was missing or zero for 5,370,484 observations. We imputed the 
days supply from the rest of the dataset using NDC number for all but 3,364 
records, which were dropped. Singly imputed values were derived from non-
missing records by NDC. 
• In order to classify records by whether they were an ER versus IR opioid 
analgesic, we matched by NDC number using a MarketScan 2011 Redbook 
master file obtained from the Centers for Disease Control and Prevention (CDC) 
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in March 2013. The CDC file had classifications for each product by ER vs. IR, 
however there were observable mistakes. We therefore used Perl regular 
expressions to find discrepancies between the literal drug name and the CDC 
classification, with the literal name considered the higher authority. Search 
strings included phrases such as “extended-release” and “controlled-release” and 
“CR”, as well as the known brand names of all market opioids. Further logic 
checks were implemented based on knowledge of the class of medicines, 
including ensuring no hydrocodone or oxycodone products were considered ER, 
all methadone was treated as ER, etc.  
• Liquids were also identified using regular expressions (e.g., “liquid,” “tincture”, 
“syrup,” etc.). 
• After reconciliation of the classification, MME conversion factors were used as 
suggested by CDC to convert each record MME by multiplying the quantity 
dispensed times the strength times the conversion factor. 
• The resulting file had 53,712,910 records. 
• Benzodiazepine, stimulant and sleep aid exposure was then determined for 
2010. 
• Prescriptions for liquids were dropped because it was not possible to determine 
the units that quantity was measured in (milliliters, vials, ampoules, etc.), thereby 
making it impossible to calculate MME: 382,872 records. 
• We analyzed data from 7,393,375 prescriptions for opioid analgesics dispensed 
for use in 2010 (including those dispensed in 2009 with days supply that ran into 
2010). 
• Data for all prescriptions active for at least part of 2010 were identified. Any that 
crossed the 2009-2010 year threshold were duplicated and treated as separate 
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prescriptions, with person-days of supply and quantity split proportional to the 
number of days in each year. Only the active prescriptions in 2010 were retained. 
• Then, each prescription active in 2010 was duplicated, one copy each 
corresponding to the start and end date. 
• A brace counting algorithm was implemented using this new date variable to 
determine the number of days between consecutively alternating open and 
closed dates, accounting for the day of dispensing.  
• The total number of days exposed in 2010 was summed for the exposure 
person-days, and the balance from 365 was treated as unexposed, with 
exposure time going into two possible observations per person. Throughout this 
process, county of residence, benzodiazepine exposure status and other 
explanatory variables were retained. 
• Dummy records were then added to the dataset, corresponding to 365 days of 
unexposed time for every NC resident who did not receive an opioid analgesic.  
• The final analysis dataset had 9,560,234 unique identifiers, with 11,261,504 
lines. 
• Since CSRS records for decedents were collected by DPH using a separate 
process, the variable formats did not allow us to positively identify the 
corresponding prescription-level records in the total CSRS dataset. Therefore, 
we created a duplicate record for each decedent, and set it to the negative value 
of any exposed time, thereby mathematically eliminating their exposed person-
time contribution when collapsed for Poisson regression.  
 Once the data were cleaned, many descriptive analyses of interest were 
possible. We were interested in assessing whether the number of unique prescribers 
for different opioids had changed over time, from 2009 through 2011. We plotted 
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time series graphs to examine this. Of particular interest was proproxyphene 
utilization after it was withdrawn from the market in early 2011. 
Time-at-risk Calculations and Determination of Dose “Cutpoints” for Aim 2 
 We explored the possibility of calculating person-time “as treated” or following 
“intent-to-treat” principles. Under the former, exposure time is only accrued during the 
time when the prescription is active. If an event occurs after the end of exposure, it 
would be classified as having occurred among the unexposed. In the intent-to-treat type 
(ITTT) method, person-time is accrued from the day the first prescription is received. As 
illustrated in Figure 3.2, there would be much less exposed time accrued (solid black 
lines) for the as-treated analysis. There would be fewer cases among the exposed (337 
as-treated; 478 for intent-to-treat) among the 629 overdose deaths in Aim 2. We felt that 
the ITTT was a more appropriate choice for person-time accrual because non-
adherence to therapy is a serious concern with opioid analgesics, especially IR 
formulations prescribed pro re nata in the outpatient setting. Put another way, once 
patients receive opioid analgesics, there is a credible expectation that they may continue 
to have them around the house if they don’t use them all. The ITTT approach better 
reflects this scenario. 
 We classified MME exposure initially by tertile and quintiles, but this led to a 
clustering of deaths at highest stratum. We then divided MME by 20 mg increments, and 
had strata with few observations at higher MME that could be collapsed to preserve 
precision. The final strata were chosen to have approximately 15 events per level.  
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Mortality and Prescription Data Linkage 
 We used a deterministic one-to-one process to link the mortality and CSRS data.  
For each overdose decedent, we identified prescriptions in the CSRS that were 
dispensed within 365 days of death using a two-step process. First, we queried each 
decedent using the web interface of the CSRS using the first five letters of their last 
name and their date of birth. Confirmatory matching was the second step, and involved 
matching the first name, last name and date of birth as recorded on the death certificate. 
Matching records were extracted electronically. The matching was conducted by staff of 
DPH and de-identified data were made available to us for analysis. 
Statistical Approach for Aim 2 
 Since an individual could be represented twice in the dataset (exposed, 
unexposed) we wanted to account violation of independence of observations assumed in 
regression models. Generalized estimating equations (GEE) offered a flexible and 
efficient solution that could be used in conjunction with Poisson regression to estimate 
rates. GEEs use the quasi-likelihood method to solve for parameters. GEE also have the 
benefit of allowing us to use robust variance estimators to generate standard errors. The 
choice of GEE also means that we cannot use the likelihood ratio test, or similar metrics, 
because the quasi-likelihood methods does not produce a numeric solution for log-
likelihood. The general form of the Poisson equation is given below.  
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To generate state-level overdose rates for Aim 1 we used the following equation: 
   
Ln(Rate) = ln(a/n) = β0 + β1X1  
ð ln(a) = β0 + β1X1 + ln(n) 
 
Where β1 represents the number of overdoses, and n is the population at risk, and β0 is 
the intercept. For modeling in Aim 2, we used dichotomous indicators (1,0) for each level 
of the exposure variable (e.g., by MME quantile) to calculate strata-specific rates.  
 
ln(a) = β0 + [β1X1 + … + βnXn] + ln(n) 
 
To calculate the incidence rate ratio, we divided the rate for the contrasting strata of 
interest by the rate for the reference group, equivalent to back-exponentiating the 
coefficient for the indicator variable of interest to arrive at the IRR.  We multiplied the 
standard error of the coefficient by 1.96 to derive the 95 percent confidence intervals 
following standard large-sample assumptions of asymptomatic normality for the model’s 
beta coefficients.  
 Overdispersion in the Poisson models was assessed using the deviance divided 
by the degrees of freedom, with greater than 1.0 suggesting the need to consider other 
models. Overdispersion was not detected (e.g., dispersion of 1.0026757 was observed 
in the benzo exposed model).  We also fit negative binomial models (NB2) for the sake 
of comparison, and these yielded nearly identical results to the Poisson models. 
 The estimated covariance matrix was examined during model selection for 
GEEs. We also fit models specifying independent and exchangeable covariance 
structures, which yielded nearly identical results. We therefore decided to use Poisson 
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GEE with an independent structure as the final model in Aim 2, in large part because this 
model form imposed the fewest assumptions on the data. 
 Data transformations and statistical modeling were performed in Stata/MP 12.1 
(College Station, Texas, USA), running on eight parallel core processors in a Linux-
based computing system.   
Human Subjects Protection 
 This research was reviewed by the University of North Carolina Non-Biomedical 
Institutional Review Board and deemed to be exempt according to federal standards 
because mortality data and prescription data were provided in de-identified form from 
government sources.  
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FIGURES 
 Figure 3.1.  Data cleaning steps for prescription data. Flowchart of data 
transformations and cleaning steps. Numbers represent the count of unique prescription 
records in the dataset. 
All prescriptions dispensed 2009 to 2011 and recorded in 
North Carolina Controlled Substances Reporting System
(n=54,825,930)
Excluded (n=1,094,717)
 Non-North Carolina county of residence (n=964,678)
Unknown or missing drug information (n=67,064)
Non-controlled substances (n=62,975)
Missing data assessment
(n=53,731,213)
Imputed missing days supply (n=5,367,120)
Classification by active ingredient and formulation
to identify solid oral and transdermal opioid analgesics
(n=53,712,910)
Classification by year dispensed
to identify prescriptions only intended for use in 2010
(n=21,448,986)
Opioid analgesic prescriptions
intended for use in 2010
(n=7,393,375)
Excluded (n=18,303)
 Missing days supply could not be imputed (n=3,364)
 Quantity dispensed could not be determined (n=14,939)
Excluded (n=32,263,924)
 Not opioid analgesics (n=31,881,052)
 Liquids (n=382,872)
Excluded (n=14,055,611)
 Dispensed in 2011 (n=7,522,050)
 Intended for use only in 2009 (n=6,533,561)
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Figure 3.2. Visual representation of person-time accounting. Person-days were 
calculated using intent-to-treat principles. 
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CHAPTER 4 
EXPLORATION OF DEFINITIONS OF OVERDOSE MORTALITY 
Overview 
 The rate of mortality attributable to drug poisoning has risen consistently since 
the 1990s. State-based vital statistics registries estimate the incidence of drug overdose 
deaths using International Classification of Disease 10th revision (ICD-10) codes. 
Composite ICD-10-based definitions of “overdose” may include deaths that do not 
involve controlled substances while missing deaths that do.  
 We evaluated the impact of including substance use disorders and 
pharmaceutical adverse events codes in definitions of overdose. Seven proposed ICD-
10-based definitions, including ones from the Injury Surveillance Workgroup (ISW) and 
the Centers for Disease Control and Prevention (CDC), were applied to North Carolina 
mortality data from 2008 through 2011. We examined whether overdose deaths varied 
among definitions and made a proposal for a definition to be used in future research. 
Introduction 
 In the United States, the rate of mortality attributable to drug poisonings has risen 
consistently since the early 1990s [64,65]. In 2008, the national age-adjusted death rate 
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from drug poisonings was 11.9 per 100,000, making it the leading cause of injury death, 
surpassing motor vehicle-related fatalities [66]. Drug poisoning mortality outpaces 
injection-borne infectious diseases, including HIV and viral hepatitis, as the leading 
cause of death among young injection drug users in the United States [67]. 
 Since 1999, national mortality data have been coded using the International 
Classification of Disease 10th Revision (ICD-10) maintained by the World Health 
Organization. Using ICD-10, each death is assigned a single underlying cause and up to 
20 contributing causes. To compute incidence estimates for poisonings, death certificate 
data and medical examiner case records are tabulated in state and territorial vital 
statistics systems, and reported nationally through the National Vital Statistics System of 
the National Center for Health Statistics (NCHS) for the Centers for Disease Control and 
Prevention (CDC).  
 There is considerable interest in the timely and accurate identification of deaths 
from ingesting psychotropic (controlled) substances in amounts that directly cause or 
contribute to a fatality (consistent with the US Food and Drug Administration (FDA) 
definition of a serious adverse event; 21 CFR § 314.80). For controlled substances the 
most relevant ICD-10 codes are: poisoning by narcotics and hallucinogens (X42, X60 
and Y12; unintentional, intentional and undetermined intent, respectively); and three 
codes (X41, X61, Y11) that include other controlled substances, such as sedatives and 
other psychotropic drugs, as well as less frequently prescribed non-controlled medicines 
for epilepsy and Parkinson’s disease that are dopaminergic precursors or otherwise 
increase dopamine activity. We collectively refer to these codes (X42, X60, Y12, X41, 
X61, Y11) as “poisonings from controlled substances.” 
 The National Center for Injury Prevention and Control (NCIP) and NCHS identify 
drug poisoning deaths only using X- and Y- chapter poisoning codes (Table 4.1) [68]. 
However, there is concern that using these codes alone may underestimate overdose 
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deaths in surveillance data [69,70]. The multi-disciplinary Injury Surveillance Workgroup 
(ISW) of the Safe States Alliance recently suggested five possible consensus-based 
recommendations of ICD codes to be used for identifying overdose events, based on 
more expansive definitions that include substance use disorder and a wide list of 
pharmaceutical adverse event codes [3,71]. However the inclusion of non-controlled 
medicines in the definition may overestimate overdose events. 
 We evaluated definitional issues of using ICD-10 codes for drug overdose death 
surveillance in a two-step process. First, we assessed the effect of including substance 
use disorder codes with the goal of implementing a more inclusive (“broad”) definition of 
drug overdose involving controlled substances. Second, we evaluated the effect of 
excluding deaths due to pharmaceutical adverse events in “broad” surveillance 
definitions for drug overdose involving controlled substances.  
 All of the NCHS and ISW definitions (Table 4.1) include deaths from 
pharmaceutical adverse events, even if the medicines involved were not controlled 
substances [3,28,72]. We could not find a clear justification for this. The FDA has used 
some of these exact codes to identify adverse event deaths unrelated to controlled 
substances, for example when reviewing the risk of infection associated with 
corticosteroid treatment [73,74]. Discrepancies such as these between federal health 
agencies necessitate a closer look at the definitions of overdose. This study explored 
which pharmaceutical adverse event deaths should be included in definitions of 
overdose mortality for controlled substances. This topic is of significance worldwide, for 
surveillance and incidence estimates and for researchers seeking to evaluate 
interventions to prevent overdoses from controlled substances. 
 We applied seven ICD-10 based definitions of “drug poisoning” or “overdose” to 
four years of mortality data from North Carolina (NC). NC vital statistics data are 
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collected in a statewide electronic medical examiner records system overseen by the 
North Carolina Office of the Chief Medical Examiner [70]. 
 
Methods 
 
 The study population was any NC resident whose death was recorded in NC vital 
statistics as having occurred from January 1, 2008 through December 31, 2011.  
 
Mortality Data Source 
 Each death triggers a registration of the death with a local or municipal health 
authority, a mandated administrative task. The cause-of-death is determined by local 
health directors, attending physicians, or medical examiners based on autopsies or other 
investigations. Once the cause(s) of death are determined, the death record is 
appended, i.e., with the literal words used to describe the cause of death, which may 
occur months after the issuance of the original certification of death. The death records 
are converted by individual nosologists or computer software to alphanumeric ICD-10 
codes. Mortality data for 2008 through 2010 were obtained from the North Carolina Vital 
Statistics Dataverse at The Howard W. Odum Institute for Social Science of the 
University of North Carolina at Chapel Hill [63]. Vital statistics mortality data for 2011 
were obtained from the Injury and Violence Prevention Branch, North Carolina Division 
of Public Health, Department of Health and Human Services, as were death certificate 
data listing the literal text of the cause-of-death fields for 2010 and 2011. 
 
Definitions 
 We analyzed one definition of overdose used by NCHS, five consensus-based 
definitions proposed by ISW, and one used for surveillance of opioid-related mortality by 
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public health authorities in Australia [71]  (Table 4.1). Definitions 1, 2, and 3 are intended 
to broadly identify all overdoses due to “drugs” and controlled substances. Definitions 4, 
5, and 7 are intended to specifically identify opioid overdoses, whereas Definition 6 only 
identifies prescription opioid overdoses. All seven definitions include the aforementioned 
six codes for poisonings from controlled substances. All definitions include homicidal 
poisoning using drugs or biological substances (X85). The definitions can also include 
deaths due to substance use disorders (Definitions 2, 3, 4, 7), pharmaceutical adverse 
events (all), the involvement of heroin (all except Definition 6), cocaine and other drugs 
(Definitions 1, 2, 3), or unspecified narcotics (all except Definition 6).  
 Substance use disorder codes are found in chapter F of ICD-10, with the 
following two-digit number indicating the substance, e.g., opioids are F11. A fourth digit 
suffix indicates the chronicity of substance use that led to the death. The codes of 
greatest relevance for mortality are: acute intoxication (.0), harmful use (.1), dependence 
syndrome (.2), withdrawal (.3), and unspecified chronicity (.9). The presence of an acute 
intoxication code (e.g., F11.0 for opioids) is in conflict with unintentional poisoning code 
(e.g., X42 for opioids). Accordingly, in 2007 NCHS discontinued the use of acute 
intoxication F codes for underlying cause-of-death in favor of X- and Y- chapter 
poisoning codes [3] (this convention may have continued at the state level beyond 
2007). However, substance use disorder codes of other chronicity (e.g., not .1) 
continued to be used. 
 Among the seven definitions, pharmaceutical adverse events were identified 
using three approaches, the first of which uses poisoning codes as underlying causes 
(X40, X43, X44, X60, X63, X64, Y10, Y13, Y14). This results in Definitions 1 through 6 
including deaths from controlled substances and non-controlled medicines. Some of 
these are: non-opioid analgesics, fever reducers (aspirin), tumor necrosis factor 
inhibitors, acetylcholine, albuterol, atropine, propanol, and ergotamine, as well as “other 
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and unspecified drugs that act on the autonomic nervous system or elsewhere.” We 
collectively refer to these as “poisonings from other and unknown substances.” 
 In the second approach, Definitions 2 and 4 also include deaths with an 
underlying cause in the range of Y40 through Y59, which are poisonings resulting from 
medicines causing adverse events during therapeutic use, i.e., iatrogenic exposures. 
Medicines could include: anti-coagulants, antibiotics, bacterial vaccines, 
immunosuppressive agents, angiotensin-converting-enzyme (ACE) inhibitors, and 
others. Of particular interest is Y45.0 which designates deaths due to the use of opioids 
and related analgesics during therapeutic use. The third way to identify adverse events 
is by using outcomes codes that suggest physiologic harm. ISW constructed Definitions 
2 and 4 to include 34 specific drug-induced underlying causes including medicine-
induced versions of conditions such as aplastic anemia, pancreatitis, gout, obesity, 
osteoporosis, and lupus erythematous, traditionally used for pharmaceutical adverse 
event reporting. We collectively refer to these as “adverse events during therapeutic 
use.” 
 The Australian surveillance definition (Definition 7) uses a different approach to 
specifically identify opioid overdose deaths (Table 4.1). It includes deaths due to any 
underlying cause that is opioid related, defined as the presence of any of the following in 
contributing cause-of-death fields: T40.0, T40.1, T40.2, T40.3, T40.4, T40.6, or F11 [71]. 
For example, Definition 7 includes deaths with underlying causes for asthma or chronic 
obstructive pulmonary disease (COPD) that also have contributing causes that show 
opioid toxicity. None of the other definitions include these cases but they are likely cases 
of interest to us. 
 To examine the involvement of multiple controlled substances in overdose 
deaths, we defined controlled substance toxicology collectively as the following ICD-10 
codes: opioids (T40.0, T40.1, T40.2, T40.3, T40.4), cocaine (T40.5), “narcotic” 
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unspecified (T40.6), benzodiazepines (T42.4), amphetamine-type stimulants (T43.6), 
ketamine (T41.2), cannabis (T40.7), hallucinogens (T40.8, T40.9), barbiturates (T42.3) 
and gamma hydroxybutyrate (T52.8). Ethanol toxicity (T51.0) was considered 
separately. The intent of the ICD-10 schema is that these codes are not intended to 
represent the mere presence of the substance in post-mortem toxicology findings or 
circumstantial evidence, but rather indicate their causal involvement in the fatality. 
 
Statistical Analysis 
 We compared seven definitions to each other using bivariate and descriptive 
statistics, with particular attention to Definition 1 because it is used by NCHS.  Variables 
of interest included: sex, race and ethnicity, age, marital status, whether an autopsy was 
conducted, and place of death. Sex differences were examined because differences in 
opioid effects have been documented in clinical trials [75,76]. Age and racial differences 
have been observed in opioid metabolism [77,78] and dependence [79]. We also 
compared definitions on whether the death was intentional, unintentional or of 
undetermined intent. Previous analyses have noted empirical interstate variation in the 
classification of intent of overdose deaths [36] and we explored whether variations within 
a state could also be ascertained. All data analysis was conducted in STATA 12 
(College Station, Texas). Population rates were calculated using Poisson regression with 
population denominators from NCHS bridged population estimates.  
 
Results 
Describing Drug Overdose Deaths 
 There were 322,458 deaths recorded in vital statistics for North Carolina from 
January 1, 2008 through December 31, 2011. Of these, 312,287 deaths were among 
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North Carolina residents, after removing two decedents for whom exact dates of death 
were missing. Among the resulting records, 4,898 deaths (1.5%) fit at least one of the 
seven definitions during the four-year study period. Definition 1 used by NCHS and 
Definition 3 proposed by ISW identified exactly the same deaths (Table 4.2).   
 Annual drug poisoning mortality rates among North Carolina residents were 12.7 
per 100,000 residents in 2008, 12.3 in 2009, 11.2 in 2010, and 12.6 in 2011, using 
Definition 1 or 3. Nearly all deaths were certified by medical examiners (95.8%) or 
physicians (3.4%), with 37 occurring outside of NC certified by coroners. Autopsies were 
performed in 76.6% to 88.4% of cases depending on the definition, with the prescription 
opioid-specific definitions (Definitions 4 through 7) more likely to have had an autopsy 
performed. By comparison, 7.2% of all deaths among NC residents had an autopsy 
performed. 
 The seven mortality definitions shared common demographic characteristics. The 
sex distribution showed minor variation, ranging from 38% female in the most opioid-
specific definitions to 41% for the broader ones (Table 4.3). The racial and ethnic 
distribution of decedents meeting Definition 1 or 3 was non-Hispanic white (89.0%) or 
black (8.0%), Native American (1.8%), any race Hispanic (0.9%), and other races and 
ethnicities (0.3%). The opioid-specific definitions had a slightly higher percent of white 
non-Hispanic decedents, for example 92.5% in Definition 5. Marital status at time of 
death was known for 99.5% of decedents included in Definition 1 or 3. One-third of the 
decedents never married, one-third were married at the time of death, and a quarter 
were divorced. The age distributions generally had a smaller peak in the mid-to-late 20s, 
a second greater peak in the middle-to-late 40s, and rapid decline thereafter. 
 The seven definitions had similar proportions of intentional, unintentional, and 
intent-unspecified deaths. As an example, Definition 1 or 3 had 3,761 (81.1%) that were 
unintentional, 694 (15.0%) that were intentional or suicides, and 178 (3.8%) of 
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undetermined intent. Only two deaths from poisoning homicide with controlled 
substances were identified, both in children. 
 Prescription opioids were involved in 61% to 63% of all drug overdose deaths 
identified using Definitions 1, 2, and 3, Table 4.3. When reviewing definitions restricted 
to opioids (definitions 4 through 7) in North Carolina, prescription opioids were involved 
in 90% to 91% of all deaths involving opioids, whereas heroin was identified in 7.7% to 
7.9% of all deaths involving opioids. Cocaine was implicated in 8.5% to 9.7% of the 
opioid-specific deaths (Definitions 4 through 7). 
 Definition 2 identified the greatest number of overdose deaths.  However, 
definition 7 identified the greatest number of opioid overdose deaths since it could 
include any underlying cause-of-death, Table 4.3. The two broadest ISW Definitions 4 
and 5 only differed by 12 deaths since they take the same approach of relying on toxicity 
codes in contributing cause fields for the identification of opioid deaths. For the sake of 
brevity the former was not considered in subsequent analysis. 
 
Identifying Pharmaceutical Adverse Event and Substance Use Disorder Codes 
 Since we were concerned about a potential underestimate of overdose deaths, 
we focused our attention on the two definitions that identified the most cases, Definition 
2 for all drugs and Definition 7 for opioid-related deaths. Definition 2 included 4,807 
(annual average: 1,202) deaths during four years, representing a 3.7% increase over the 
4,635 deaths (annual average: 1,159) identified with Definition 1 or 3, Figure 4.1. 
Poisonings due to controlled substances made up 68.6% (n=3,299) of drug overdose 
deaths identified using Definition 2 (Table 4.4 and white circle in Figure 4.1). However 
1,334 poisoning deaths from other and unknown substances make it difficult to 
understand which substances were implicated. Deaths in this category were of interest 
because theoretically some could have been excluded since they are pharmaceutical 
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adverse events not involving controlled substances. The underlying cause-of-death field 
provides little additional information; 94% were due to a trio of codes for “poisoning by 
other and unspecified drugs, medicaments and biological substances”: X44 (n=887), 
X64 (n=303), and Y14 (n=69), of unintentional, intentional, and undetermined intent, 
respectively. However, the contributing cause-of-death fields provided additional 
information to characterize these deaths. Despite an underlying cause-of-death that 
suggested that the substance involved was unknown, 586 of the 1,334 deaths had 
controlled substance toxicity codes as contributing causes (Figure 4.1, left box): opioids 
(n=553), cocaine (n=369), benzodiazepines (n=86), and amphetamine-type stimulants 
(n=24), with more than one controlled substance toxicity code in 362 records. Of the 
remaining 748 deaths, the only toxicology code listed for 52.5% (n=393) records was 
“unspecified drugs, acidifying agents, alkalizing agents, immunoglobulin, parathyroid 
hormones” (T50.9). Among the remaining 355 deaths, 61 had codes for disorders due to 
the use of multiple substances (e.g., F19). That left 294 deaths that had toxicology 
codes for a variety of medicines that had no evidence of involving controlled substances: 
anti-allergic and antiemetic drugs, acetaminophen, respiratory system agents, non-
steroidal anti-inflammatory drugs, insulin and oral diabetes medicines, aspirin, anti-
coagulants, calcium-channel blockers, cardiac-stimulant glycosides and anti-dysrhythmic 
drugs, and anti-depressants, Figure 4.1. These do not appear to be deaths of interest for 
this analysis.  
 Another way to assess the contribution of pharmaceutical adverse events is by 
comparing the 172 additional overdose deaths identified using Definition 2 versus 
Definitions 1 or 3 (Figure 4.1, grey penumbra). This also provides insight into the 
importance of including substance use disorder codes. Among the 172 deaths there 
were 112 with substance use disorder underlying causes (F11 to F19), including 
sedatives, cocaine, amphetamine-type stimulants, and multiple drugs (Figure 4.1, right 
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box). The F codes were used in deaths statewide and do not appear to be an artifact of 
isolated individual medical examiner conventions. The median age of decedents with 
substance use disorder codes was 50.0 years (IQR: 42.5, 58), compared to 42 years 
(IQR: 31, 50) for poisonings from controlled substances, Table 4.4. Other demographic 
characteristics were similar between deaths identified using the substance use disorder 
and poisonings from controlled substances codes.  
 Of the remaining 60 deaths, 58 deaths were caused by adverse events involving 
medicines in therapeutic use (Y40 through Y59) (Figure 4.1, right box). Only two deaths 
were due to controlled substances, specifically opioids during therapeutic use (Y45.0). 
As a group, the deaths involving adverse events during therapeutic use were older 
(median 65.5 years, IQR: 48, 77.5) than substance use disorder deaths or poisonings 
from controlled substances, Table 4.4, and may not be a death from an overdose of the 
type in which we are interested. 
 Two remaining deaths due to pharmaceutical adverse events were identified 
using Definition 2 proposed by ISW one from drug-induced secondary Parkinsonism 
(G21.1) and one death from drug-induced myopathy (G72.0). These two deaths also do 
not appear to be of interest in this analysis, as there were multiple co-morbid conditions 
and both deaths were among 70-year-olds. 
 
Expanding the Definition 
 We also explored whether the approach in Definition 7 of including deaths with 
controlled substance poisoning and toxicology codes in contributing cause-of-death 
fields would change the number of drug overdose deaths identified. Including deaths 
with any underlying cause that have contributing causes among the six controlled 
substance poisoning codes (X41, X42, X61, X62, Y11, Y12) adds 108 deaths not 
identified by Definition 2, Figure 4.1. Similarly, Definition 2 did not include 126 deaths 
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where controlled substance toxicology codes were present. There was an overlap of 90 
deaths between these two approaches, so a total of 145 additional deaths were 
identified that may be drug overdoses from controlled substances, Figure 4.1. The most 
common underlying causes were circulatory system disorders, such as non-congestive 
heart failure. 
 There were 145 overdose deaths involving controlled substances that were not 
identified using either the NCHS or ISW definitions, Figure 4.1. These deaths were 
identified by allowing records with any underlying cause with at least one contributing 
cause from among the controlled substance poisoning or toxicity codes. For example, 
the death of a 32-year-old male had an underlying cause of pneumonitis from aspirated 
vomit, but was accompanied by a controlled substance poisoning X code, adult 
respiratory distress syndrome, and opioid, benzodiazepine and cocaine toxicity codes. 
These deaths should be considered for inclusion in overdose definitions for controlled 
substances (Table 4.5). 
Discussion 
 We propose a refined definition that borrows upon the work of NCHS, ISW and 
the Australians (Definition 8, Table 4.5). Conceptually starting with the definition that 
identified the greatest number of records (Definition 2 from the ISW) our proposed 
definition removes 354 deaths that were due to pharmaceutical adverse events and 
homicide, and adds 145 deaths not previously identified, yielding 4,598 overdose deaths 
involving controlled substances during four years, indicated in Figure 4.1 with asterisks. 
The total number of deaths among NC residents over four years identified using the 
NCHS definition (Definition 1) (n=4,635) and our proposed definition (n=4,598) differ only 
slightly.  
 In addition to the three broad definitions for overdose deaths from controlled 
substances, we evaluated four opioid-specific ones (including three proposed by ISW) 
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for the sake of completeness and because deaths involving opioids have become a 
major public health concern [65]. Also, we borrowed concepts from Definition 7 
described by Jauncey and colleagues (2005) in proposing our own definition.  
 The ICD defines T50.9 as a catchall for medical products not explicitly mentioned 
in the coding schema, including medicines acting on the cardiovascular and gastro-
intestinal system, hormones, antibiotics, vaccines, and topical preparations, to name a 
few. The choice to include the 393 records in our proposed definition can be called into 
question, as there may be a desire by some to only attribute events to controlled 
substances where a specific psychotropic drug is identified (e.g., positive evidence). 
While we acknowledge that this code may result in including deaths from non-controlled 
substances, given the lack of standardization of assays, autopsy, and coding practices, 
the absence of negative evidence implores us to consider these deaths in the definition. 
One practical solution would be to conduct a sensitivity analysis with and without the 
T50.9-only poisonings deaths, and present both results. In our study, the number of 
overdose deaths would accordingly range from 4,205 to 4,598, a change of less than 
100 deaths per year. 
 We entertained the possibility of including deaths with controlled substance use 
disorder codes in contributing cause fields. While there were some deaths that could 
possibly have been due to overdose, the most common underlying causes of death 
included chronic harms of injection drug use, such as viral hepatitis and HIV. In some of 
these instances the last exposure to the substance may have been days, or even 
decades, ago. It is possible that our proposed definition is also an underestimate of the 
actual overdose deaths from controlled substances. 
 In the absence of a gold standard against which to compare definitions of 
overdose deaths using vital statistics we have chosen to focus on internal validity. This is 
the primary limitation of our analysis. We anticipate that the availability of electronic 
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health records and medical examiner systems will allow us to compare overdose deaths 
identified in vital statistics with those identified using medical records in the future, 
extending analyses of others [11].  
 It is possible that not all deaths determined to be overdoses by medical 
examiners are accordingly identified [80,81]. To address this concern, qualitative and 
quantitative methods that include interviews with active drug users, overdose survivors 
and family members of decedents can be used [10,29,82,83,84]. It may also be 
important to differentiate instances where illicitly manufactured drugs may contain 
contaminants that are the primary cause-of-death [85], and the controlled substance is in 
low concentration. Further work is needed to uncover what convention coding practices 
are under this scenario. 
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TABLES AND FIGURES 
 
Table 4.1. ICD-10-based definitions for identifying drug overdose deaths. 
 
	   	  
Substance Use Pharmaceutical
Disorders Adverse Event
1
National 
Center for 
Health 
Statistics drug 
poisoning
Any underlying COD: X40-X44, X60-
X64, X85, and Y10-Y14 • • • • • •
2
Acute or 
chronic 
poisonings due 
to the effects of 
drugs from 
ISW [9]
Deaths with underlying COD: D52.1, 
D59 (.0, .2), D61.1, D64.2, E06.4, 
E16.0, E23.1, E24.2, E27.3, E66.1, 
F11-F16, F19, G21.1, G24.0, G25 (.1, 
.4, 6), G44.4, G62.0, G72.0, I95.2, 
J70 (.2-.4), K85.3, L10.5, L27 (.0, .1), 
M10.2, M32.0, M80.4, M81.4, M83.5, 
M87.1, R50.2, X40-X44, X60-X64, 
X85, Y10-Y14, or Y40-Y59
• • • • • • •
3
Acute 
poisonings due 
to the effects of 
drugs from 
ISW [9]
Deaths with underlying COD: [F11 - 
F16] (.0), F19.0, X40-X44, X60-X64, 
X85, or Y10-Y14
• • • • • •
Deaths with an underlying COD code: 
F11 or Y45.0
----- or -----
Underlying cause-of-death:
D52.1, D59 (.0, .2), D61.1, D64.2, 
E06.4, E16.0, E23.1, E24.2, E27.3, 
E66.1, F12-F16, F19, G21.1, G24.0, 
G25 (.1, .4, 6), G44.4, G62.0, G72.0, 
I95.2, J70 (.2-.4), K85.3, L10.5, L27 
(.0, .1), M10.2, M32.0, M80.4, M81.4, 
M83.5, M87.1, R50.2, X40-X44, X60-
X64, X85, Y10-Y14, Y40-Y44, or Y46-
Y59 
and
Any contributing COD: F11, T40.0, 
T40.1, T40.2, T40.3, T40.4, T40.6
Deaths with underlying COD: [F11 - 
F16] (.0), F19.0, X40-X44, X60-X64, 
X85, or Y10-Y14 
and
Any contributing COD: F11.0, T40.0, 
T40.1, T40.2, T40.3, T40.4, T40.6
Deaths with an underlying COD: [F11 - 
F16] (.0), F19.0, X40-X44, X60-X64, 
X85, or Y10-Y14 
and
Any contributing COD: T40.2, T40.3, 
T40.4
7
All possible 
opioid-related 
deaths 
Australian 
surveillance 
definition [8]
"Opioid toxicity” means T40.0 to T40.4 
and T40.6 are present in any 
contributing COD field. Any death that 
has: (1) underlying COD F11.0-F11.9; 
(2) underlying COD X42, with 
contributing COD opioid toxicity; (3) 
underlying COD X44, with contributing 
COD opioid toxicity; (4) underlying 
COD F19.0-F19.9, with either 
contributing COD opioid toxicity, or 
F11.0-F11.9; (5) underlying COD X60-
X69 with opioid toxicity; (6) underlying 
COD Y10- Y19 with opioid toxicity; (7) 
underlying COD F10, F12-F18 with 
opioid toxicity; (8) underlying COD 
X85 with opioid toxicity; (9) underlying 
COD X40-X41 or X43-X49 with opioid 
toxicity; (10) any underlying COD with 
opioid toxicity not otherwise specified; 
(11) any underlying COD with F11.0 
through F11.9 as a contributing COD
• • • • • •
8
Proposed 
definition of 
overdoses 
involving 
controlled 
substances
See Table 4.5 • • • • • •
• •
6
Acute drug 
poisonings 
associated with 
the effects of 
opioid 
analgesics 
• •
5
Acute drug 
poisonings 
associated with 
the effects of 
opium, heroin 
and/or opioid 
• •
Unspecified 
Narcotics
4
Acute or 
chronic drug 
poisonings 
associated with 
the effects of 
opium, heroin 
and/or opioid 
analgesics 
from ISW [9]
• • • • • •
Cause-of-Death Substances Involved
# Title ICD-10 Codes Poisoning Prescription Opioids Heroin
Cocaine and 
Other Drugs
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2008 2009 2010 2011 4 year total
1 North Carolina drug overdoses 1,180 1,162 1,071 1,222 4,635
2 Acute or chronic poisonings due to the effects of 
drugs (ISW)
1,222 1,201 1,114 1,270 4,807
3 Acute poisonings due to the effects of drugs 
(ISW)
1,180 1,162 1,071 1,222 4,635
4 Acute or chronic drug poisonings associated 
with theffects of opium, heroin, and/or opioid 
analgesics (ISW)
840 843 757 782 3,222
5 Acute drug poisonings associated with the 
effects of opium, heroin, and/or opioid 
analgesics (ISW)
839 836 755 780 3,210
6 Acute drug poisonigns associated with the 
effects of opioid analgesics (ISW)
765 763 707 703 2,938
7 Australia all possible opioid-related 797 781 691 753 3,022
1
2
3
4
5
6
7
Deaths with an underlying cause of death code of F11 or Y45.0 OR deaths with an underlying cause of death 
code of D52.1, D59 (.0, .2), D61.1, D64.2, E06.4, E16.0, E23.1, E24.2, E27.3, E66.1, F12-F16, F19, G21.1, 
G24.0, G25 (.1, .4, 6), G44.4, G62.0, G72.0, I95.2, J70 (.2-.4), K85.3, L10.5, L27 (.0, .1), M10.2, M32.0, 
M80.4, M81.4, M83.5, M87.1, R50.2, X40-X44, X60-X64, X85, Y10-Y14, Y40-Y44, or Y46-Y59 AND one or 
more of the following codes in any multiple cause of death field: F11, T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 
Deaths with an underlying cause of death code of [F11 - F16] (.0), F19.0,
X40-X44, X60-X64, X85, or Y10-Y14 and one or more of the following codes in any multiple cause of death 
field: F11.0, T40.0, T40.1, T40.2, T40.3, T40.4, T40.6 
Deaths with an underlying cause of death code of [F11 - F16] (.0), F19.0, X40-X44, X60-X64, X85, or Y10-
Y14 AND one or more of the following codes in any multiple cause of death field: T40.2, T40.3, T40.4
"Opioid toxicity” means T40.0 to T40.4 and T40.6. Deaths includes are: (1) underlying cause of death F11.0 
through F11.9; (2) underlying cause of death X42, with contributing cause of death due to opioid toxicity; (3) 
underlying cause of death X44, with contributing cause of death due to opioid toxicity; (4) underlying cause of 
death F19.0-F19.9, with either contributing cause of death due to opioid toxicity, or F11.0-F11.9; (5) X60 
through X69 with opioid toxicity; (6) Y10 through Y19 with opioid toxicity; (7) F10, F12 through F18 with opioid 
toxicity; (8) X85 with opioid toxicity; (9) X40 through X41 or X43 through X49 with opioid toxicity; (10) opioid 
toxicity in any contributing cause-of-death field not otherwise specified; (11) mental and behavioral disorder 
due to use of opioids F11.0 through F11.9 in any contributing cause-of-death field
Table&4.2.!Annual!overdose!deaths,!by!fatal!overdose!definition,!NC!residents,!2008!though!2011.
Definitions
Definitions of drug poisonings
Definitions of opioid poisonings
Any underlying or contributing cause-of-death: X40-X44, X60-X64, X85, and Y10-Y14
Deaths with an underlying cause of death code of D52.1, D59 (.0, .2), D61.1, D64.2, E06.4, E16.0, E23.1, 
E24.2, E27.3, E66.1, F11-F16, F19, G21.1, G24.0, G25 (.1, .4, 6), G44.4, G62.0, G72.0, I95.2, J70 (.2-.4), 
K85.3, L10.5, L27 (.0, .1), M10.2, M32.0, M80.4, M81.4, M83.5, M87.1, R50.2, X40-X44, X60-X64, X85, Y10-
Y14, or Y40-Y59
Deaths with an underlying cause of death code of [F11 - F16] (.0), F19.0, X40-X44, X60-X64, X85, or Y10-
Y14
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4 year total % Female % Cocaine % Heroin % Rx opioid
1 North Carolina drug overdoses 4,635 41.3% 13.8% 5.5% 63.4%
2 Acute or chronic poisonings due to the effects of 
drugs (ISW)
4,807 41.4% 13.3% 5.3% 61.1%
3 Acute poisonings due to the effects of drugs 
(ISW)
4,635 41.3% 13.8% 5.5% 63.4%
4 Acute or chronic drug poisonings associated 
with the effects of opium, heroin, and/or opioid 
analgesics (ISW)
3,222 38.4% 9.7% 7.9% 91.2%
5 Acute drug poisonings associated with the 
effects of opium, heroin, and/or opioid 
analgesics (ISW)
3,210 38.5% 9.5% 7.9% 91.5%
6 Acute drug poisonings associated with the 
effects of opioid analgesics (ISW)
2,938 40.3% 8.5% 1.1% 100.0%
7 Australia all possible opioid-related 3,022 37.2% 10.0% 8.4% 89.3%
1
2
3
4
5
6
7
Deaths with an underlying cause of death code of F11 or Y45.0 OR deaths with an underlying cause of death code of D52.1, 
D59 (.0, .2), D61.1, D64.2, E06.4, E16.0, E23.1, E24.2, E27.3, E66.1, F12-F16, F19, G21.1, G24.0, G25 (.1, .4, 6), G44.4, 
G62.0, G72.0, I95.2, J70 (.2-.4), K85.3, L10.5, L27 (.0, .1), M10.2, M32.0, M80.4, M81.4, M83.5, M87.1, R50.2, X40-X44, X60-
X64, X85, Y10-Y14, Y40-Y44, or Y46-Y59 AND one or more of the following codes in any multiple cause of death field: F11, Deaths with an underlying cause of death code of [F11 - F16] (.0), F19.0,
X40-X44, X60-X64, X85, or Y10-Y14 and one or more of the following codes in any multiple cause of death field: F11.0, T40.0, 
T40.1, T40.2, T40.3, T40.4, T40.6 
Deaths with an underlying cause of death code of [F11 - F16] (.0), F19.0, X40-X44, X60-X64, X85, or Y10-Y14 AND one or 
more of the following codes in any multiple cause of death field: T40.2, T40.3, T40.4
"Opioid toxicity” means T40.0 to T40.4 and T40.6. Deaths includes are: (1) underlying cause of death F11.0 through F11.9; (2) 
underlying cause of death X42, with contributing cause of death due to opioid toxicity; (3) underlying cause of death X44, with 
contributing cause of death due to opioid toxicity; (4) underlying cause of death F19.0-F19.9, with either contributing cause of 
death due to opioid toxicity, or F11.0-F11.9; (5) X60 through X69 with opioid toxicity; (6) Y10 through Y19 with opioid toxicity; (7) 
F10, F12 through F18 with opioid toxicity; (8) X85 with opioid toxicity; (9) X40 through X41 or X43 through X49 with opioid 
toxicity; (10) opioid toxicity in any contributing cause-of-death field not otherwise specified; (11) mental and behavioral disorder 
due to use of opioids F11.0 through F11.9 in any contributing cause-of-death field
Table&4.3.&Drug&toxicology&codes&reported,&by&fatal&overdose&definition,&NC&residents,&2008&though&2011.
Definitions
Definitions of drug poisonings
Definitions of opioid poisonings
Any underlying or contributing cause-of-death: X40-X44, X60-X64, X85, and Y10-Y14
Deaths with an underlying cause of death code of D52.1, D59 (.0, .2), D61.1, D64.2, E06.4, E16.0, E23.1, E24.2, E27.3, E66.1, 
F11-F16, F19, G21.1, G24.0, G25 (.1, .4, 6), G44.4, G62.0, G72.0, I95.2, J70 (.2-.4), K85.3, L10.5, L27 (.0, .1), M10.2, M32.0, 
M80.4, M81.4, M83.5, M87.1, R50.2, X40-X44, X60-X64, X85, Y10-Y14, or Y40-Y59
Deaths with an underlying cause of death code of [F11 - F16] (.0), F19.0, X40-X44, X60-X64, X85, or Y10-Y14
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ICD$10'Codes Underlying'Cause$of$Death n Percent Median'age IQR
X41'X61'Y11'X42'X62'Y12 Poisonings'from'
controlled'substances
3,299 68.6% 42 31,'50
X40'X43'X44'X60'X63'X64'Y10'
Y13'Y14
Adverse'events'from'non$
controlled'and'unknown'
substances
1,334 27.7% 44 33,'52
F11'F12'F13'F14'F15'F16'F19 Substance'use'disorders** 112 2.3% 50 42.5,'58
D521'D590'D592'D611'D642'
E064'E160'E231'E242'E273'E661'
F12'F13'F14'F15'F16'F19'G211'
G240'G251'G254'G256'G444'
G620'G720'I952'J702'J704'K853'
L105'L270'L271'M102'M320'
M804'M814'M835'M871'R502'
Y40'Y41'Y42'Y43'Y44'Y45'Y46'Y47'
Y48'Y49'Y50'Y51'Y52'Y53'Y54'Y55'
Y56'Y57'Y58'Y59
Adverse'events'during'
therapeutic'use**
60 1.2% 65.5 48,'77.5
X85 Poisoning'homicide 2 <'0.1% 0,'5
Total 4,807
IQR:'interquartile'range
**'Not'included'in'Definition'1'or'3.
Table&4.4.&Deaths&from&different&causes&among&decedents&identified&using&Definition&2*,&North&Carolina&residents,&
from&2008&through&2011.
*'Cases'were'identified'as'those'deaths'with'underlying'cause$of$death:'D52.1,'D59'(.0,'.2),'D61.1,'D64.2,'E06.4,'
E16.0,'E23.1,'E24.2,'E27.3,'E66.1,'F11$F16,'F19,'G21.1,'G24.0,'G25'(.1,'.4,'6),'G44.4,'G62.0,'G72.0,'I95.2,'J70'(.2$.4),'
K85.3,'L10.5,'L27'(.0,'.1),'M10.2,'M32.0,'M80.4,'M81.4,'M83.5,'M87.1,'R50.2,'X40$X44,'X60$X64,'X85,'Y10$Y14,'or'
Y40$Y59.
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Steps ICD)10,Codes
1.#Include#all#deaths#with#an#underlying#COD#
for#poisonings#from#controlled#substances
X41#X61#Y11#X42#X62#Y12
2.#Include#deaths#with#an#underlying#COD#
from#poisonings#due#to#unknown#and#other#
substances#only#if#there#is#an#associated#
controlled#substance#toxicology#code
X40#X43#X44#X60#X63#X64#Y10#Y13#Y14#
and#controlled#substance#toxicology#
codes
3.#Include#deaths#with#an#underlying#COD#
from#poisonings#due#to#unknown#and#other#
substances,#where#no#controlled#substance#
toxicology#is#specified,#but#a#controlled#
substance#use#disorder#code#is#present#in#
contributing#COD
X40#X43#X44#X60#X63#X64#Y10#Y13#Y14#
and#controlled#substance#use#disorder#
codes
4.#Include#deaths#with#an#underlying#COD#
from#poisonings#due#to#unknown#and#other#
substances,#where#no#controlled#substance#
toxicology#is#specified,#no#controlled#
substance#use#disorder#code#is#present#in#
contributing#COD,#but#the#only#poisoning#T#
code#is#T50.9
X40#X43#X44#X60#X63#X64#Y10#Y13#Y14#
and#T50.9
5.#Include#deaths#with#underlying#COD#of#a#
controlled#substance#use#disorder
F11#F12#F13#F14#F15#F16#F19
6.#Include#deaths#with#underlying#COD#of#
Y45.0
Y45.0
7.#Among#deaths#not#yet#included,#add#those#
records#where#there#is#controlled#substance#
toxicity#or#controlled#substance#poisoning#in#
the#contributing#COD#fields,#but#no#X85#in#
the#underlying#COD
X85#and#controlled#substances#
poisoning#and#toxicology#codes
Definitions
Controlled#substance#toxicology#codes T40.0#T40.1#T40.2#T40.3#T40.4#T40.6#
T40.5#T42.4#T42.3#T43.6#T41.2#T40.7#
T40.8#T40.9#T52.8
Controlled#substance#use#disorder#codes F11#F12#F13#F14#F15#F16#F19
Poisoning#T#codes T36#through#T65
Controlled#substance#poisoning#codes X41#X61#Y11#X42#X62#Y12
Table,4.5.,Proposed,ICD)10)based,definition,of,overdose,mortality,from,controlled,
substances,for,vital,statistics,(Definition,8)
ICDN10:#International#Classification#of#Disease,#10th#revision
COD:#causeNofNdeath
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Figure 4.1. Schematic representation of definitions of drug overdose deaths, North 
Carolina residents, 2008 through 2011. This figure depicts the definitions that yielded 
the greatest number of possible drug overdose deaths, and a breakdown of the 
component causes-of-death that contribute to the definitions. The asterisks (*) designate 
deaths included in the definition for drug overdose mortality proposed in this paper. The 
large white circle in the middle is overdose deaths identified using Definitions 1 or 3 
(n=4,635). An additional 112 deaths were identified using Definition 2, larger darker 
circle, and can be broken down into three mutually exclusive categories of substance 
use disorders, pharmaceutical adverse events and iatrogenic opioid deaths, right grey 
box. The enclosed grey circle represents 1,334 poisoning deaths from other and 
unknown substances. These deaths can be further broken down into four mutually 
exclusive categories as shown in the left box. The two overlapping circles in the top left 
depict possible overdose deaths not identified by Definition 2. The proposed definition 
removes 354 deaths that were due to pharmaceutical adverse events and homicide, and 
adds 145 deaths not previously identified, resulting in a total of 4,598 overdose deaths 
during the four years of observation. Please refer to text and Table 4.5 for exact ICD-10 
codes used for each definition. Note that the circle for the additional deaths not identified 
by Definition 2 (overlapping circles in top left) and the homicide circle are not drawn to 
scale. 
 
 
 
 
	   57	  
Figure 4.2. All drug and opioid overdose death rates, North Carolina 
residents, 2008 through 2011. Overdose mortality by month using Definitions 1 
(solid black line) and 4 (dashed line). 
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CHAPTER 5 
A PROSPECTIVE COHORT STUDY OF OPIOID ANALGESICS 
AND OVERDOSE MORTALITY  
Overview 
 Opioid analgesics have been associated with dose-dependent increases in overdose 
risk. There is limited safety data on overdose risk at higher doses that are relatively common 
in clinical practice (e.g., over 150 mg per day). In addition, there is little information on 
comparative risks between immediate-release (IR) and extended-release (ER) formulations, 
and whether the dose-dependent effect is influenced by central nervous system depressant 
benzodiazepines. 
 We conducted a prospective cohort study of all North Carolina residents (n=9,560,234) 
in 2010, using electronic controlled substances prescription monitoring program data. 
Exposure of 1,133,957 person-years to opioid analgesics was observed using intent-to-treat 
principles. Overdose deaths were identified from medical examiner records and vital 
statistics. Incidence rates, rate differences, and incidence rate ratios were calculated using 
regression models to describe the rate of overdose at higher doses of opioid analgesics. 
Introduction 
 The use of opioids in the management of pain has long been tempered with concerns 
about fatal overdose arising from respiratory depression. The United States and Canada 
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have the highest per capita consumption of opioids in the world and the highest overdose 
rates as well [25]. The public health problem created by the inappropriate use of opioid 
analgesics is pervasive, however in much of the world, strong opioid analgesics are 
unavailable even for end-of-life pain control among cancer patients [86].  
 Part of the resistance regarding opioid use may stem from safety concerns at high doses 
and increasing trends of overdose deaths in the United States and Canada. At the societal 
level, many studies over the last 15 years have suggested a linear ecologic association 
between the total mass of opioids dispensed and overdose morbidity and mortality 
[4,5,6,7,8,9,10,11,12]. Simply summarized: the more opioid analgesics that are prescribed, 
the greater the overdose morbidity and mortality involving these substances are observed at 
the population level. 
 In contrast, at the individual level, there continues to be legitimate concern that those 
experiencing pain in the United States and Canada do not receive basic analgesic relief, 
even in the context of massive opioid prescribing. For example, studies of pain in nursing 
homes and hospices consistently reveal that they receive inadequate pain treatment [87,88]. 
Some patients who could benefit from pain relief are not medicated, and, even if the patients 
are receiving opioids, the dose may not be sufficient to address pain needs [89].  
 Among the pharmaceutical opioid formulations available in the United States and 
Canada, there is a broad distinction between immediate-release (IR) formulations (dosage 
every four to six hours), and extended-release (ER) formulations (dosage once or twice per 
day). IR opioids are intended for use in acute or breakthrough pain, and often come 
combined with paracetamol (acetaminophen) or ibuprofen, whereas ER opioids are 
indicated for chronic pain and contain larger amounts of active ingredient per tablet or 
deliver medicine via a transdermal patch.  
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 Few individual-level studies have examined the association between higher doses of 
opioid analgesics and overdose mortality in the United States and Canada [13,14,15,16,17]. 
The five individual-level studies with overdose deaths as an outcome are summarized in 
Table 5.1. All studies show increasing risk of overdose mortality with dose strength. 
However direct comparison between studies is difficult because of variations in whether 
deaths due to illicit drugs and suicide were included, which opioid analgesics were 
considered in the exposure, and whether relative effect measures included comparison to 
opioid unexposed individuals in the general population as part of the reference group. In 
addition, these studies offer limited information on the gradient of risk above 200 mg per day 
of morphine equivalents, despite widespread use over this level. Only one study reported 
separate rates of IR versus ER opioid analgesics [15], and one adjusted for formulation in 
models [16]. None of the studies examined whether the dose-dependent effect may be 
influenced by co-prescribed benzodiazepines, a well-established risk factor for respiratory 
depression [65,90,91]. 
 As described above, strong associations have been observed between amount of 
opioids dispensed and overdose mortality. Yet, clinical trials and their meta-analyses 
consistently show safety of opioid analgesics at high doses [18,19,20,21,22]. To explore this 
paradox we conducted a prospective cohort study among North Carolina residents in 2010 
to quantify dose-dependent overdose risk in routine clinical practice. We suspected that the 
routine clinical practice of outpatient pain management may be sufficiently different from the 
clinical trial setting as to lead to increased risk of overdose in the general population. 
 We hypothesized that ER opioids would be associated with greater overdose mortality 
than IR opioids, including at higher doses. We based this hypothesis on ecological studies 
that suggest a linear association between the mass of opioid analgesics dispensed and 
overdose mortality at the population level, and the fact that ER opioids have more milligrams 
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of active ingredient per unit than IR opioids. We also hypothesized that the dose-dependent 
risk of mortality associated with opioid analgesics could partially be explained by additional 
attributable risk from exposure to co-prescribed benzodiazepines. 
 Our study has three goals. First, to describe patterns of clinical opioid analgesic 
utilization, focusing on prescribers, prescriptions, and patients, with attention to opioid 
substance and formulation type. Second, we examine the relationship between high dose 
opioid analgesic prescribing and overdose mortality, and whether benzodiazepines may 
influence the dose-dependent response. Third, we examine whether there are differences 
between IR and ER opioid analgesics on overdose mortality. 
Methods 
Data Sources 
 The North Carolina Controlled Substances Reporting System (CSRS) is a state-
mandated prescription monitoring program in operation since 2007. CSRS data are 
generated when prescriptions for a controlled substance are dispensed at regulated 
pharmacies in North Carolina. The data captured include each field of information legally 
required to be on a prescription for a controlled substance including: the drug name, quantity 
of units, date of dispensing, and prescriber and pharmacy Drug Enforcement Agency (DEA) 
registration numbers. Data are stored locally at the pharmacy and transmitted within two 
weeks of dispensing to a central database owned by the NC Division of Mental Health, 
Developmental Disabilities and Substance Abuse Services (DMHDDSAS). The database is 
maintained under contract by Health Information Designs (Auburn, Alabama, United States), 
using the RxSentry database management tool. We were provided with a dataset that 
included a unique identifier for each recipient of a controlled substance derived using a 
proprietary de-duplication algorithm. Due to federal policy and state laws, the CSRS does 
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not receive prescriptions data from pharmacies in Veterans Administration and Department 
of Defense facilities, Indian Health Service clinics, physician in-clinic dispensing, veterinary 
clinics, and outpatient opioid dependence treatment programs. 
 Death certificate data from North Carolina’s State Center for Health Statistics were used 
to identify overdose deaths. We then obtained electronic records on these decedents from 
the Office of the Chief Medical Examiner (OCME). All deaths that occurred in North Carolina 
were certified by licensed medical examiners or attending physicians. The post-mortem 
serum toxicological analyses were conducted as part of autopsy and included drug details 
for all major controlled substances, differentiating between types of pharmaceutical opioids 
and isomers of diacetylmorphine (heroin).  
 Data on the numbers of total licensed clinicians practicing in the state in 2010 were 
obtained from state medical licensure boards, via the North Carolina Health Professions 
Data System stored at the Cecil G. Sheps Center for Health Services Research, University 
of North Carolina at Chapel Hill.  
Study Design 
 We structured our analysis as a prospective cohort study of all NC residents in 2010. 
Exposure was defined as having received a dispensed prescription of an opioid analgesic 
for use in 2010. The outcome was overdose mortality involving opioid analgesics. Mortality 
rates were calculated using regression models. 
Data Linkage 
 We used a deterministic one-to-one process to link the mortality and CSRS data.  For 
each overdose decedent, we identified prescriptions in the CSRS that were dispensed within 
365 days of death using a two-step process. First, we queried each decedent using the web 
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interface of the CSRS using the first five letters of their last name and their date of birth. 
Confirmatory matching was the second step, and involved matching the first name, last 
name and date of birth as recorded on the death certificate. Matching records were 
extracted electronically. 
Exposure Definition 
 Figure 5.1 depicts the data cleaning process in detail. A total of 54,825,930 records for 
dispensed prescriptions were available for analysis from 2009 through 2011. First, we 
removed prescriptions dispensed to non-residents, records with unknown or missing drug 
information, and non-controlled substances (n=1,094,717). Next, person-days were 
calculated using a measure typically referred to as “days supply.” Days supply is a legally 
required prescription element, and is defined by the prescriber, noted on the prescription, 
and incorporated in a field of the CSRS database. Days supply was truncated to 182 days 
for 1,228 prescriptions for opioid analgesics of greater duration because these illogical 
values fell outside of DEA guidelines for controlled substances prescribing. Days supply was 
imputed for 5,369,748 prescription records with missing or zero days supply by assigning 
the median days supply from the rest of the dataset, matched by quantity and National Drug 
Code (NDC) number (the NDC number is a FDA-issued unique product identifier that 
encompasses strength, formulation, active ingredient and manufacturer). Some records 
were excluded because drug name and NDC number were missing or the quantity 
dispensed could not be determined (n=18,303). 
 We then positively identified 21,448,986 prescriptions for solid oral or 
transdermal opioid analgesics labeled for acute and chronic pain containing codeine, 
hydrocodone, hydromorphone, fentanyl, methadone, morphine, oxycodone and 
oxymorphone. Of these, 7,393,375 prescription records were intended for use in 2010. 
 64	  
 We used a two-step process to identify prescriptions for opioid analgesics. The active 
ingredient, milligram strength, and formulation type (e.g., extended-release/immediate-
release, and solid oral/patch/liquid) were determined by matching by NDC number using a 
commercial standard MarketScan 2011 Redbook master file obtained from the Centers for 
Disease Control and Prevention (CDC) in March 2013. Second, to maximize inclusion of 
data with incorrect or missing NDC numbers, a regular expressions-based parser on the 
drug name field was utilized to determine the active ingredient and formulation, with 
discrepant prescriptions reviewed individually to determine the correct assignment using the 
drug name field as the standard (via REGEXM in Stata). Of the eight opioid substances 
analyzed in this paper, two were available only as IR (codeine, hydrocodone), and five were 
available as both ER and IR (fentanyl, hydromorphone, morphine, oxycodone, 
oxymorphone). In tablet form, methadone is used for chronic pain management, and as a 
liquid for management of opioid dependence; for consistency with regulatory classification 
we included methadone tablets in the ER category [92]. 
 In order to explore whether the opioid formulation (ER versus IR) modified the 
relationship between MME and overdose risk among those who had received any opioid 
analgesic, we dichotomized residents by IR opioid status, with one category containing 
those who had only received IR opioid prescriptions, versus those who had at least one ER 
prescription, in the 365 days prior to death or end of the study. We similarly dichotomized 
benzodiazepine exposure status to ascertain if any benzodiazepine exposure may influence 
overdose risk. We assessed the impact of stratification on incidence rate ratios by inspecting 
overlapping 95 percent confidence intervals resulting from regression models. 
 We calculated the average daily dose in terms of milligram equivalence to morphine. 
Because of the differences in potencies between opioids, clinicians refer to equianalgesic 
conversion tables when switching patients from one opioid to another during opioid rotation; 
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conversion ratios by active ingredient are standardized to morphine. In order to have 
comparable results with previous studies, we used the conversion ratios suggested by CDC: 
codeine (0.15), fentanyl (25.0), hydrocodone (1.0), hydromorphone (4.0), methadone (3.0), 
morphine (1.0), oxycodone (1.5) and oxymorphone (3.0) (Leonard Paulozzi, personal 
communication, March 1, 2013). Total milligrams of MME per prescription were calculated 
by multiplying the milligrams per dosage unit times the quantity of units dispensed times the 
conversion factor. The average daily MME per individual in 2010 was calculated by taking 
the total milligrams and dividing by the days supply, taking into account overlapping 
prescription days for each individual. Two concurrent prescriptions for 30 days (e.g., an 
extended-release opioid for chronic pain and an immediate-release opioid for breakthrough 
pain) would both contribute milligrams to the numerator but the total person-days of 
exposure would be 30 if the prescriptions were completely contemporaneous.  Four 
individuals with MME greater than 5,000 milligrams per day were outliers and not included in 
regression models because they did not experience overdose deaths during the observation 
period. 
Outcome Definition 
 We included residents who died in 2010 and whose underlying cause-of-death was an 
unintentional or undetermined drug overdose (ICD-10 codes X40-X44, Y10-Y14). The role 
of each drug in the death was determined by OCME toxicologists according to a 
standardized classification system, drawing from investigations at the scene of death, 
toxicological findings, available medical records, and interviews. Two categories of drug 
involvement were analyzed: primary (the drug was at a concentration sufficient to have 
caused the death alone regardless of other drugs detected), and additive (the drug was at a 
concentration not sufficient to have caused the death alone but acted in an additive manner 
with other drugs to have caused the death). We did not include cases where opioid 
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analgesics’ contribution to death was circumstantial only, such as when drugs were present 
but determined not to have played a role in the death. For cocaine, heroin, and ethanol, 
however, we also included the presence of these substances in descriptive analyses. 
Records for 2010 were abstracted into a database using a standardized extraction form for 
decedents with available toxicology results, corresponding to 824 (92%) deaths identified 
using vital statistics and ICD-10 codes. Because we were interested in the class-level effect 
of exposure to opioid analgesics, we defined the outcome event as any overdose where at 
least one of the eight opioid substances was deemed by the medical examiner to be a 
primary or additive substance that directly contributed to death. 
Access to Care Definition 
 Using data from the North Carolina Health Professions Data System we defined the 
number of potential controlled substance prescribers as all state-licensed physicians 
(n=20,752), nurse practitioners (n=3,679), physician assistants (n=3,652), and dentists 
(n=4,178), and an estimated 100 clinical pharmacist specialists [93]. As a proxy for an 
access-to-care measurement, we calculated what proportion of all potential prescribers 
wrote dispensed prescriptions for opioid analgesics by dividing the number of unique NC-
registered DEA numbers for each prescription type recorded in the CSRS by the total 
number of NC-based licensed clinicians eligible to obtain a DEA registration number to 
prescribe controlled substances (n=32,361). 
Analysis  
 We first sought to understand opioid analgesic prescribing practices through descriptive 
analyses. We plotted the number of prescribers, prescriptions and patients who received 
opioid analgesics in 2010, stratifying by formulation type (extended-release or immediate-
release) and active ingredient. To gain a better understanding of opioid overdose mortality, 
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we examined age and sex distributions of decedents, and the contributions of ethanol, 
heroin, and cocaine. We also explored whether the opioid ingredients involved in death had 
been prescribed to the decedent in the previous 365 days. 
 Our analysis was a prospective cohort study of all North Carolina residents in 2010.  The 
state population was represented by the mid-year population of 9,560,234 persons 
estimated by the National Vital Statistics System [94]. Individuals without a prescription 
record for an opioid analgesic in the CSRS contributed unexposed person-days for all of 
2010.   
 Data were analyzed according to intent-to-treat (ITT) principles where an individual was 
considered exposed from the date of the first opioid prescription in 2010 among individuals 
who did not experience an event. For overdose decedents, first date of opioid prescription in 
the 365 days preceding death was used as the starting point to allow for equal potential 
observation time to those who did not have the outcome. The ITT approach has been 
suggested for use in observational safety studies of pharmacotherapy because it reduces 
bias arising from excluding those who stop therapy or are lost to follow-up, is used 
extensively in the clinical trial setting, and avoids inducing selection bias during follow-up 
that would result from censoring the outcomes of those who changed treatment [95]. 
Person-days exposed and unexposed to opioids were calculated separately, and accrued in 
calendar year 2010 or in the 365 days prior to overdose death. Therefore each individual 
could have either one or two records in the analysis dataset, corresponding to the person-
days exposed and unexposed. 
 Stratified mortality rates were calculated by dividing the number of deaths by person-
years of exposure calculated using intent-to-treat principles. Standard errors were calculated 
using the exact method [96]. Number needed to harm was calculated by taking the inverse 
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of the rate difference between mortality at different levels of MME for ER versus IR opioid 
analgesic exposure. Incidence rate ratios were calculated using Poisson regression with 
person-days at risk as the offset, implemented with generalized estimating equations (GEE) 
to account for repeated observations of an individual [97,98]. An independent structure was 
assigned after initial inspection of the covariance matrix. Standard errors were calculated 
using the Huber-White robust variance method [99], with the modification of subtracting the 
number of covariates from the number of observations. Data transformations and statistical 
modeling were performed in Stata/MP 12.1 (College Station, Texas, USA), running on 8 
parallel core processors in a Linux-based computing system.   
Human Subjects Protection 
 This research was reviewed by the University of North Carolina Non-Biomedical 
Institutional Review Board and deemed to be exempt according to federal standards. 
Results 
Opioid Analgesic Utilization Patterns 
 A total of 2,182,374 North Carolina residents received opioid analgesics for use in 2010, 
representing 22.8% of the total population, Figure 5.2. The most commonly dispensed 
opioids were hydrocodone and oxycodone, Figure 5.3. Immediate-release formulations were 
dispensed to 22.5% of the population (n=2,154,949), whereas 1.4% (n=139,520) received 
extended-release opioid analgesics. Immediate-release formulations accounted for 
6,535,257 prescriptions, and extended-release accounted for 858,118 prescriptions, a ratio 
of about 15-to-2.  
 Residents filled prescriptions for opioid analgesics written by 28,998 North Carolina-
based prescribers. Prescriptions for opioid analgesics came from 89.6% (n=28,998) of all 
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licensed clinicians in the state. By way of comparison, opioid analgesics were the most 
commonly prescribed type of controlled substance: 83.3% (n=26,953) of licensed clinicians 
prescribed benzodiazepines, 57.2% (n=18,518) sleep aids, and 44.8% (n=14,487) 
stimulants. 
 Fewer licensed clinicians had records indicating they prescribed extended-release 
opioids 40.0% (n=12,939), compared to immediate-release opioids 88.5% (n=28,649). The 
more potent synthetic opioids had the lowest numbers of prescribers: oxymorphone 6.2% 
(n=2,006), methadone 16.2% (n=5,256), hydromorphone 24.8% (n=8,037), and fentanyl 
25.0% (n=8,087).  
 We observed 61,879 patients who received more than 150 mg average daily MME. Of 
these, 24.9% (n=15,430) of patients received their entire dose only in IR opioid formulations, 
while the remaining received both IR and ER opioids. Among those receiving more than 150 
mg/day MME as only IR, the median intended duration of use indicated on the prescription 
was 4 days (IQR: 1, 30), however 14.1% (n=2,176) were on therapy for longer than 182 
days. 
Overdose Deaths 
 There were 629 deaths involving opioid analgesics in a primary or additive role among 
North Carolina residents in 2010, Figure 5.2. Females (n=234) comprised 37.2% percent of 
decedents, and the median age for both sexes was 43 years (inter-quartile range: 32 to 51 
years). Deaths among females peaked a few years earlier than males. The most common 
pharmaceutical opioids involved in overdose deaths were: oxycodone, methadone, 
hydrocodone and fentanyl, Figure 5.3. Ethanol was involved in 12.2% (n=77) of overdoses 
involving opioid analgesics. Heroin was present in only 1.3% (n=8) of opioid analgesic 
overdoses, whereas cocaine was present in 8.4% (n=53). 
 70	  
 Among the 629 deaths, 24.0% (n=151) had no record of having being dispensed a solid 
oral or transdermal opioid analgesic in the 365 days prior to death. Among the 478 
decedents who had received an opioid, 43.1% (n=208) had received at least one extended-
release formulation. Only half of all decedents (51%, n=244) had a current prescription at 
the time of death, confirming the decision to calculate exposure according to intent-to-treat 
principles. 
Extended-release and Immediate-release Opioid Analgesics 
 There were 2,181,843 person-years of opioid analgesic exposure accrued during the 
study period calculated according to intent-to-treat principles, with 478 overdose deaths 
among patients receiving opioid analgesics for use in 2010, Table 5.2. Rates of overdose 
death increased incrementally as average daily MME increased, Table 5.2 and Figure 5.4. 
Incidence rates appeared to increase gradually, but stayed elevated beyond 200 mg/day 
MME. Using the lowest opioid exposed group (average daily MME dose >0 to 39.9 mg/day) 
as a reference, once 200 mg/day MME had been achieved, rates of overdose did not 
increase substantially with increasing dose. 
 Rates of overdose were about ten times greater among those receiving ER and IR 
opioid analgesics in combination, 14.9 per 10,000 person-years (95 percent CI: 12.9, 17.1), 
compared to those receiving only IR opioid analgesics, 1.3 per 10,000 person-years (95 
percent CI: 1.2, 1.5), Table 5.3 and Figure 5.5. When compared to patients receiving the 
same MME of opioid analgesics, mortality rates among patients receiving ER and IR in 
combination were higher than those receiving only IR opioid analgesics. At the lowest strata, 
>0 to 99.9 mg/day average daily MME, the rate difference was 5.0 per 10,000 person-years, 
increasing to 7.5 per 10,000 person-years for 100 to 149.9 mg/day and stabilizing at 7.7 per 
10,000 person-years at higher doses. Correspondingly, the number needed to harm ranged 
 71	  
from 2,003 to 1,291. 
Benzodiazepines  
 The percent of all opioid analgesic recipients who were also prescribed a 
benzodiazepine was 80.0% (n=1,747,166). Benzodiazepines were implicated in 61.4% 
(n=386) of overdose deaths involving opioid analgesics. Rates of overdose death were 
about ten times higher among those receiving benzodiazepines in combination with opioid 
analgesics (7.0 per 10,000 person-years, 95 percent CI: 0.6, 0.9), compared to only opioid 
analgesics (0.7 per 10,000 person years, 95 percent CI: 6.3, 7.8), Table 5.4 and Figure 5.6. 
When compared to patients receiving the same MME of opioid analgesics, differences in 
mortality rates among those receiving benzodiazepines was greater at higher opioid 
analgesic doses. At the lowest stratum, >0 to 74.9 mg/day average daily MME, the rate 
difference was 2.8 per 10,000 person-years, increasing to 45.8 per 10,000 person-years at 
the highest stratum of 300 to 5,000 mg/day average daily MME. Correspondingly, the 
number needed to harm ranged from 3,623 to 218. 
Discussion 
 This study reports findings from a large prospective cohort study of opioid analgesic use. 
Five previous studies have attempted to quantify the dose response between opioid 
analgesics and mortality, Table 5.1. Our analysis has more than three times as many 
exposed patients as the next largest published study. Our results extended the knowledge 
of the relationship between opioid dose and mortality by clarifying dose-specific risks of 
overdose for a more nuanced gradient of opioid analgesic doses than previous studies, 
including a dose range routinely used in clinical practice. This study is one of the first to 
quantify the additional risk of death associated with ER opioid analgesics. We also 
documented that the dose-dependent relationship between opioid analgesic dose and 
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overdose mortality is strongly influenced by concurrent benzodiazepine exposure, especially 
in the presence of higher opioid doses. 
 In our study, the incidence rate of overdose mortality appeared to rise gradually at lower 
doses, and increase distinctly at doses greater than 200 mg average daily MME. Like 
previous studies, we observed a dose-response relationship between MME and mortality 
risk, but we were also able to clarify that the shape of the curve is not linear. There appears 
to be relatively small additional risk of overdose death after patients reach 200 mg average 
daily MME, relative to the lowest strata, on the log-linear scale. We suspect that influences 
of clinical management may explain the change in the trajectory, with patients receiving 
higher doses of opioid analgesics receiving closer attention from the treating physician and 
caregivers, mitigating some of their risk for overdose. Opioid tolerance may also be part of 
the explanation for the shape of the curve. Increased opioid tolerance results in a rightward 
shift of the median effective dose, which may be accompanied by a corresponding shift in 
the median toxic dose, resulting in a broader or shifted therapeutic window where 
medication errors may be less likely to lead to respiratory depression. Unlike previous 
studies, we did not observe a meaningful inflection of the incidence rate at 100 mg/day 
average daily MME [14]. While the absolute rate of overdose continued to rise, above 200 
mg average daily MME there was slowing increased overdose risk with subsequent 
increases in MME dose on a log-linear scale.  
The results are consistent with our hypothesis that ER opioids would be associated 
with higher rates of overdose than IR opioids at comparable levels of MME. At lower doses 
(less than 100 mg/day MME), for approximately every 2,000 patients treated for a year with 
ER opioid analgesics instead of IR, there would be one additional overdose death. At higher 
doses, there would be one additional overdose death for approximately every 1,300 patients 
treated for a year with ER instead of IR opioid analgesics. Stated in terms of benefit and 
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risk, our results lead to the following question: Do the benefits of around-the-clock pain 
control using high dose ER opioid analgesics among 2,000 patients for a year outweigh the 
grief caused by a single untimely death? The answer to this question can only be derived 
from collective discussion, and highlights the need for additional information on the nature of 
the benefits of ER opioid analgesics experienced by patients. By way of comparison, the 
number needed to harm is reported to be 112 for suicidality associated with anti-depressant 
use among adolescents [100].  
To inform the answer to the question presented above, we must also understand the 
underlying prevalence of chronic pain and the availability of treatment. The authors of a 
telephone-based study using a stratified probability sample of North Carolina households 
reported that approximately 10% of respondents suffered from chronic disabling back pain 
[101]. There are concerns that limiting the number of clinicians who prescribe ER opioids 
may adversely affect pain patients’ ability to achieve analgesic relief, construed as an 
“access to care” problem, especially among racial and ethnic minorities [102]. While “access 
to care” is a commonly described concern in pain management, there have been few 
attempts to quantify it. While increased prescribing by primary care doctors has led to wider 
access to pain treatment, a general concern is that non-specialized clinicians may not have 
been adequately trained to prescribe these medications safely [103]. This analysis is one of 
the first to quantify the extent of prescribing of ER and IR opioid analgesics among all 
licensed clinicians in a population-based study, which provides a clearer picture of what 
access to opioid therapy may mean at a population level. While it may not be surprising that 
89.6% of licensed clinicians prescribe opioid analgesics, we were surprised that so many 
(40.0%) had prescribed an ER opioid at least once in the previous year. We also report that 
22.8% of the population received an opioid analgesic in 2010, and 1.4% received an ER 
opioid analgesic, consistent with the national estimate of 1.2% for 2009 presented by FDA 
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based on commercially available data [104] (and in line with utilization patterns from other 
high-income countries [105]). As a society we urgently need to understand what level of ER 
opioid prescribing would strike the correct balance between access to care concerns and 
inadequately trained physicians. We also need to objectively understand and quantify what 
benefits patients receive from ER versus IR opioid analgesics.  
Many dosage strengths of ER opioid analgesics have approved single unit doses 
greater than 100 mg/day MME. There is limited information from general practice settings to 
guide clinical decisions at higher doses. Comparing to the most similar published study to 
ours, the range of our observed effect measures (IRR 2.6 through 6.7 for categories up to 
119.9 mg/day) were lower than the odds ratio (OR) reported by Paulozzi et al. for average 
daily MME of 40 to 120 mg/day (OR 12.2, 95% CI: 9.2, 16.0). Our effect measures were 
greater than theirs (OR 11.3, 95% CI: 8.1, 15.8) for the highest categories, with IRR ranging 
from 16.6 through 90.4. This may be explained in part by the fact that that study combined 
unexposed and low-exposure individuals in the referent category, but also included suicides 
and deaths involving only illicitly manufactured drugs, limiting direct comparison. Despite 
this, the curves plotting relative risk against average daily MME from both studies were very 
similar in shape (e.g., Figure 2 in Paulozzi et al.), although we were able to provide greater 
resolution at higher doses. 
We also found that benzodiazepines were prescribed to eight-out-of-ten patients 
receiving opioid analgesics. At opioid analgesic doses less than 75 mg/day MME, there was 
one additional overdose death from concurrent receipt of a benzodiazepine for 
approximately every 3,600 patients treated for a year with opioid analgesics. At the highest 
doses, there was one additional overdose death attributable to concurrent benzodiazepine 
exposure for every 218 patients treated for a year with opioid analgesics. Is there a 
substantial benefit to patients who receive both benzodiazepines and opioid analgesics to 
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justify co-prescribing them? While the risk of overdose from combinations of opioid 
analgesics and benzodiazepines has been well-documented in samples of drug users and 
toxicology studies [91], our results suggest that much of the previously noted dose-
dependent mortality associated with opioid analgesics in general may be due to the 
widespread clinical practice of giving patients both classes of central nervous system 
depressants.  
 Given that 24% of decedents had no recent prescription history, it is clear that some of 
the drugs used in overdose deaths are obtained through social sharing outside of 
sanctioned medical use. Our findings suggest that history of opioid analgesic prescription is 
neither necessary nor causal to experience an overdose, but that opioid availability from a 
licensed clinician is one factor in a likely complex individual risk environment [58,59,106]. 
 Many high dose IR opioids contain paracetamol (acetaminophen). Patients receiving 
these does may also experience hepatic injury, leading to morbidity, and possibly even 
death [107]. Among the overdose deaths we examined, none had a contributing cause-of-
death suggesting liver injury, however diagnostic suspicion bias may have influenced this 
observation and we cannot preclude hepatic injury contributing to death. Since our focus 
was on overdose involving opioid analgesics caused by respiratory depression, our 
methodology would not have detected deaths where the underlying cause-of-death was 
hepatic injury that may be a result of high levels of exposure to paracetamol 
(acetaminophen) from IR opioids. According to North Carolina vital statistics data, there 
were 18 deaths in 2010 possibly related to paracetamol (acetaminophen) toxicity (ICD-10 
codes: K71.1, Y45.5, Y10, X40, T39.9, T39.1), but we acknowledge there may be 
underreporting cases. Only two of these deaths included codes consistent with possible 
controlled substances poisoning, but both were deemed to be intentional (e.g., suicide). We 
speculate that if there were more exact ascertainment of cause-of-death, and probable 
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deaths involving hepatic injury and opioid analgesics had been included, the difference 
between IR and ER opioids might be even wider than observed. 
 It is welcome news that opioid analgesic and benzodiazepine co-prescribing is common, 
but is not associated with observable increases in risk at higher doses. While we cannot 
conclude that concomitant benzodiazepine use is generally safe at higher opioid doses, it 
appears that mortality risk is more closely linked to average daily opioid dose than the co-
prescription of benzodiazepines. 
Strengths and Limitations.  
 Population-based cohort studies of limited-duration like ours have the benefit of limiting 
selection bias such as that arising from changes due to patient selection over multiple years 
of observation. They also avoid the complications inherent in selection of controls in case-
control studies. Another strength of our study is that the toxicological assessment conducted 
was able to distinguish between heroin and its metabolites, most notably morphine, thereby 
allowing us greater specificity in identifying outcomes of interest. Our data indicate that 
132,732 patients in North Carolina received doses of opioid analgesics greater than 100 
average daily MME in 2010, and this level can be reached by a single tablet or patch of 
many ER opioid analgesics. There is clearly a place for high-dose opioid formulations in 
modern medicine. However, previous research provided little insight on risks above 100 
MME by treating higher doses all the same. 
 The study has limitations. First, our models assumed continuous risk during exposed 
and unexposed time. This assumption is unlikely to be tenable at higher opioid doses; the 
riskiest time may be after the initiation of therapy. We also did not take into account previous 
duration on therapy. External factors could have influenced overdose mortality during our 
observation period. Efforts to increase access to treatment for opioid dependence, 
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prescriber education programs for pain management, and harm reduction programs are 
known to have existed in North Carolina in 2010 [108]. All studies relying on medical 
examiner or vital statistics data are subject to limitations on identifying overdose [70]. As 
with the other studies on this topic, we also cannot eliminate the possibility that patients 
obtained opioid analgesics from other states or from outside medical distribution channels. 
Similarly, we cannot assume that a patient took the entire dispensed prescription as 
instructed. Therefore the actual exposure may have differed somewhat from the prescribed 
dose. 
 Two changes in the pharmaceutical supply of opioid analgesics occurred during the 
study. First, August 2010 saw the release of a new formulation of a commonly abused 
medicine (OxyContin, oxycodone extended-release) with features that made it more difficult 
to crush for injection or insufflation. Second, propoxyphene was withdrawn from the United 
States market on November 19, 2010, leading to the possibility that patients were switched 
to full mu-opioid receptor agonists in preparation for the lack of availability. These will be 
explored in future analyses. 
 There is an inherent question of exchangeability when comparing patients at different 
doses of the same medication in observational studies. Patients receiving higher doses are 
more likely to have more serious illnesses which necessitate, at least in the mind of the 
clinician, higher doses. The direct comparison of IR and ER opioid analgesics within strata 
of MME may be less influenced by this bias, and both showed elevated risks of overdose 
from reference groups. Even though we did not have covariate information that would allow 
us to adjust for likelihood of receiving treatment, observational studies such as ours might 
offer insight into medical practice outside of the clinical trial setting where high doses of IR 
opioids containing paracetamol (acetaminophen) would be unethical. In addition, the use of 
equianalgesic conversion factors treats all opioids as the same, ignoring feasible subjective 
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differences between them that likely influence treatment choice, including pill burden, patient 
preference, side effect profile, adverse event risk, and insurance coverage. Simply put, a 
generic codeine tablet is not the same as a branded fentanyl patch. The results of our study 
must be interpreted in this light. 
 Deaths involving opioid analgesics result from a combination of physiologic, genetic, and 
behavioral factors, compounded by broader social determinants such as health literacy, 
poverty, access to healthcare, and further upstream causes of painful conditions from 
injuries, cancer and violence [54,106]. These characteristics may also influence the 
likelihood of receiving a prescription for an opioid analgesic. Data on these potential 
confounders are not routinely available at an individual level in large population-based 
studies, and we were not able to control for them in ours.  
Conclusion 
 
 Using the largest population-based cohort study published to date, we have quantified 
the dose-response relationship between opioid prescribing and overdose mortality, at higher 
doses than previously examined. We hope that our work will facilitate more nuanced clinical 
decisions about dose escalation. Higher doses of opioid analgesics were associated with 
increased overdose risk, however there were smaller incremental increases in risk above 
200 mg average daily MME. Much of the risk at higher doses appears to be associated with 
co-prescribed benzodiazepines. At higher doses, there would be one additional overdose 
death for approximately every 1,300 patients treated for a year with ER instead of IR opioid 
analgesics. As a society we urgently need to understand what level of ER opioid prescribing 
would strike the correct balance between access to care concerns and inadequately trained 
physicians. We also need to objectively understand and quantify what benefits patients 
receive from ER versus IR opioid analgesics. 
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TABLES AND FIGURES 
 
Table 5.1. Published studies of opioid analgesic dose and mortality. 
 
  Author Study*Years Study*Design Drug*substances Sample*Size Outcome Effect*Measure Notes
Peer$reviewed)publications
Bohnert(et(al. 2004(/(2008 Case/cohort(study(using(
medical(records(from(random(
sample(of(military(veterans,(
United(States
codeine,(morphine,(
hydrocodone,(
hydromorphone,(
oxycodone,(
oxymorphone
143,684 Unintentional(
prescription(opioid(
overdose(deaths(
identified(in(vital(
statistics,(n=750
Reference(group:(1(mg/day(to(
less(than(20(mg/day
Cancer)pain
20(to(<50(mg/day:(HR(1.7(
(95%(CI:(0.7,(4.3;(CLR(6.1)
50(to(<100(mg/day:(HR(6.0(
(95%(CI:(2.3,(15.8;(CLR(6.9)
100(mg/day(or(greater:(HR(
12.0((95%(CI:(4,4,(32.5;(CLR(
4.4)
Chronic)non$cancer)pain)
20(to(<50(mg/day:(HR(1.9(
(95%(CI:(1.3,(2.7;(CLR(2.1)
50(to(<100(mg/day:(HR(4.6(
(95%(CI:(3.2,(6.7;(CLR(2.1)
100(mg/day(or(greater:(HR(7.2(
(95%(CI:(4.8,(10.6;(CLR(2.2)
93.3%(male;(separate(
estimates(for(chronic(
pain,(cancer(pain,(
acute(pain(and(
substane(use(disorder(
history;(controls(
identified(using(5%(
random(subsample(of(
all(medical(records
Dunn(et(al. 1997(/(2005 Cohort(study(of(non/cancer(
pain(patients(receiving(opioid(
analgesics(using(data(from(
prepaid(private(health(
insurance(plan,(Washington,(
United(States
Not(specified,(but(
includes:(
hydrocodoone,(IR(and(
ER(oxycodone,(
codeine(combination,(
ER(morphine,(
propoxyphene,(
tramadol,(
hydromorphone,(
methadone,(
transdermal(fentanyl
9,940 Intentional,(
unintentional,(and(
undetermined(intent(
prescription(opioid(
overdose/related(
emergency(department(
admissions((n=45)(and((
deaths((n=6)(from(
electronic(medical(
records
Reference(group:(avergae(
MME(1(to(<(20(md/day
20(to(<50(mg/day:(HR(1.4(
(95%(CI:(0.6,(3.6;(CLR(6)
50(to(<100(mg/day:(HR((3.7(
(95%(CI:(1.5,(9.5;(CLR(6.3)
100(mg/day(or(greater:(HR(8.9(
(95%(CI:(4.0,(19.7;(CLR(4.9)
Average(daily(dose(
calculated(using(90(
day(exposure(windows
Gomes(et(al. 1997(/(2006 Nested(case/control(study(using(
records(from(individuals(
enrolled(in(a(government(
assistance(drug(benefit(
program,(Ontario,(Canada
codeine,(
hydromorphone,(
meperidine,(
morphine,(oxycodone,(
transdermal(fentanyl
607,156 "Opioid/related(deaths"(
identified(by(coroners,(
n=498
Reference(group:(Average(
MME(1(to(19(mg/day
200(mg/day(or(greater:(
adjusted(OR(2.9((95%(CI:(1.8,(
4.6;(CLR(2.5)
Ages(15(to(64(years;(
adjusted(for(previous(
medicine(use,(number(
of(drugs,(duration(of(
treatment,(number(of(
physicians,(number(of(
pharmacies,(ER(opioid(
status
Gomes(et(al. 2004 Cohort(study(of(non/malignant(
pain(patients(using(records(
from(socioeconomically(
disadvantaged(beneficiaries(of(
government(drug(assistance(
program,(Ontario,(Canada
codeine,(morphine,(
oxy/(codone,(
hydromorphone,(
meperidine(and(
transdermal(fentanyl;(
excluded(parenteral(
and(intranasal(
preparations
154,411 "Opioid/related"(deaths(
identified(in(government(
health(benefits(registry,(
n=302
Reference(group:(average(
MME(>0(to(200(mg/day
201(to(399(mg/day:(IRR(2.2(
(95%(CI:(1.92.5;(CLR(1.3)
400(mg/day(or(greater:(IRR(
2.3((95%(CI:(1.7,(3.0;(CLR(1.8)
Ages(15(to(65;(
Exposure(measured(in(
first(90(days(of(year(
and(followed/up(for(
up(to(2(years
Paulozzi(et(al. 2006(/(2008 Case/control(study(using(
government(prescription(
monitoring(prorgam(data,(New(
Mexico,(United(States
buprenorphine,(
codeine,(fentanyl,(
hydrocodone,(
hydromorphone,(
meperidine,(
methadone,(
morphine,(oxycodone,(
propoxyphene
730,381 Unintentional(overdose(
deaths(involving(
prescription(and(illicit(
drugs(identified(by(chart(
review(of(medical(
examiner(data,(n=300
Reference(group:(average(
MME(0(to(40(mg/day
>40(to(120(mg/day:(OR(12.2(
(95%(CI:(9.2,(16.0;(CLR(1.7
>120(mg/day:(OR(11.3((95%(
CI:(8.1,(15.8;(CLR(1.9)
Reference(group(
includes(individuals(
not(exposied(to(
opioids;(includes(
overdose(deaths(from(
only(illicitly(
manufactured(
substances
Current)Study
Dasgupta(et(al. 2010 Cohort(study(using(government(
prescription(monitoring(
prorgam(data,(North(Carolina,(
United(States
solid(oral,(film(and(
transdermal((forms(of:(
codeine(combination(
tablets,(fentanyl,(
hydrocodone(
combination(tablets,(
hydromorphone,(
methadone(tablets,(
morphine,(oxycodone,(
oxymorphone;(
2,182,374 Unintentional(and(
undetermined(inent(
prescription(opioid(
overdose(deaths(
identified(in(vital(
statistics,(n=629
Reference(group:(average(
MME(>0(to(39.9(mg/day
40(to(59.9(mg/day:(IRR(2.6(
(95%(CI:(2.0,(3.5;(CLR(1.8)
to
500(through(12,0000(mg/day:(
IRR(125.8((95%(CI:(84.4,(186.6;(
CLR(2.2)
See(Table(2
All(ages
Abbreviations:(confidence(interal((CI),(extended/release((ER),(hazard(ratio((HR),(immediate/release((IR),(incidence(rate(ratio((IRR),(milligrams((mg),(milligrams(of(morphine(equivalents((MME),(odds(
ratio((OR)
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Table 5.2. Incidence rates and incidence rate ratios for overdose deaths involving 
opioid analgesics, by average daily milligrams of morphine equivalents, North 
Carolina Residents, 2010. 
	  
 
 
 
  
Deaths Person+years n
Rate.per.10,000.
Person+Years
95%.Confidence.
Interval
Incidence.
Rate.Ratio
95%.Confidence.
Interval
Unexposed 151 4,700,647 7,377,860 0.3 0.27,.0.38 0.57 0.44,.0.73
>0.to.39.9.mg/day 98 259,735 1,305,969 3.8 3.1,.4.6 1.
40.to.59.9.mg/day 90 457,223 457,322 2.0 1.6,.2.4 2.6 2.0,.3.5
60.to.79.9.mg/day 47 213,813 213,868 2.2 1.6,.2.9 2.9 2.1,.4.1
80.to.99.9.mg/day 34 72,447 72,483 4.7 3.2,.6.5 6.2 4.2,.9.2
100.to.119.9.mg/day 23 45,536 45,559 5.0 3.2,.7.6 6.7 4.3,.10.6
120.to.139.9.mg/day 22 20,699 20,721 10.6 6.7,.16.1 14.1 8.9,.22.5
140.to.159.9.mg/day 14 14,585 14,599 9.6 5.2,.16.1 12.8 7.3,.22.4
160.to.179.9.mg/day 15 6,769 6,784 22.1 12.4,.36.5 29.5 17.1,.50.7
180.to.199.9.mg/day 11 9,604 9,615 11.4 5.7,.20.5 15.2 8.2,.28.4
200.to.249.9.mg/day 24 11,654 11,678 20.6 13.2,.30.6 27.4 17.5,.42.8
250.to.299.9.mg/day 20 7,405 7,425 27.0 16.5,.41.7 35.9 22.2,.58.0
300.to.349.9.mg/day 17 4,495 4,512 37.8 22.0,.60.5 50.2 30.0,.84.0
350.to.399.9.mg/day 17 3,563 3,580 47.7 27.8,.76.4 63.2 37.8,.105.7
400.to.499.9.mg/day 14 3,527 3,541 39.7 21.7,.66.6 52.7 30.1,.92.2
500.to.5,000.mg/day 32 2,892 4,718 110.6 75.7,.156.2 90.4 60.7,.134.6
Total 629 5,834,594 9,560,234 1.1 1.0,.1.2
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Deaths Person-years n Rate 95% CI
Immediate-release only
>0 to 99.9 mg/day 227 1,980,893 1,981,163 1.1 1.0, 1.3
100 to 149.9 mg/day 21 46,031 46,052 4.6 2.8, 7.0
150 to 199.9 mg/day 9 10,823 10,832 8.3 3.8, 15.8
200.0 to 5,000 mg/day 13 4,582 4,595 28.4 15.1, 48.5
Total 270 2,042,329 2,042,642 1.3 1.2, 1.5
Extended-release alone or in combination with immediate-release
>0 to 99.9 mg/day 42 68,433 68,475 6.1 4.4, 8.3
100 to 149.9 mg/day 30 24,772 24,802 12.1 8.2, 17.3
150 to 199.9 mg/day 25 15,568 15,593 16.1 10.4, 23.7
200.0 to 5,000 mg/day 111 30,742 30,855 36.1 29.7, 43.5
Total 208 139,514 139,725 14.9 12.9, 17.1
Table 5.3. Incidence rates per 10,000 person-years for overdose deaths involving 
opioid analgesics, by average milligrams of morphine equivalents and formulation 
type, North Carolina residents, 2010. 
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Deaths Person-years n Rate 95% CI
No benzodiazepine(s)
>0 to 74.9 mg/day 85 1,479,019 1,479,135 0.6 0.4, 0.7
75 to 124.9 mg/day 11 153,681 153,694 0.7 0.3, 1.3
125 to 299.9 mg/day 11 34,317 34,328 3.2 1.6, 5.7
300.0 to 5,000 mg/day 14 6,478 6,493 21.6 11.8, 36.2
Total 121 1,673,494 1,673,650 0.7 0.6, 0.9
Received benzodiazepine(s)
>0 to 74.9 mg/day 141 422,794 422,945 3.3 2.8, 3.9
75 to 124.9 mg/day 56 47,604 47,660 11.8 8.9, 15.3
125 to 299.9 mg/day 94 28,164 28,259 33.4 27.0, 40.8
300.0 to 5,000 mg/day 66 9,787 9,853 67.4 52.1, 85.8
Total 357 508,349 508,717 7.0 6.3, 7.8
Table 5.4. Incidence rates per 10,000 person-years for overdose deaths involving 
opioid analgesics, by average milligrams of morphine equivalents and 
benzodiazepine prescription status, North Carolina residents, 2010. 
 
 
 83	  
Table 5.5. Rate differences per 10,000 person-years and number needed to harm for 
overdose deaths involving opioid analgesics, by average milligrams of morphine 
equivalents, formulation type and benzodiazepine prescription status, North Carolina 
residents, 2010. 
 
  
Average daily MME
Rate difference per 
10,000 person-years
Number needed to 
harm
>0 to 99.9 mg/day 5.0 2003
100 to 149.9 mg/day 7.5 1325
150 to 199.9 mg/day 7.7 1291
200.0 to 5,000 mg/day 7.7 1293
Average daily MME
Rate difference per 
10,000 person-years
Number needed to 
harm
>0 to 74.9 mg/day 2.8 3623
75 to 124.9 mg/day 11.0 905
125 to 299.9 mg/day 30.2 331
300.0 to 5,000 mg/day 45.8 218
Additional mortality from exteneded-release opioid analgesics, 
compared to similar doses of immediate-release opioid analgesics
Additional mortality from concurrent benzodiazepine and opioid 
analgesic prescribing
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Figure 5.1. Data cleaning steps for prescription data used in study, North Carolina, 
2009 through 2011. Numbers in figure represent the unique count of prescription records 
included or excluded at each data cleaning step. 
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Figure 5.2. Study participant patient flow diagram, North Carolina residents, 2010. 
This schematic represents the number of individuals who were included in analyses. 
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Figure 5.3. Percents of prescribers, prescriptions, patients receiving opioid 
analgesics, and overdose deaths, by active ingredient and formulation, North 
Carolina Residents, 2010. Numbers in parenthesis in the figure represent the approximate 
relative potency to morphine. Columns 1, 3, 4, and 5 do not sum to 100% because 
individuals could appear in more than one category. The denominator for column 1 is all 
licensed clinicians in North Carolina including doctors, nurse practitioners, physician 
assistants, and clinical pharmacists (n=32,361). The denominator for column 2 is the total 
number of prescriptions dispensed for opioid analgesics (n=7,393,375). Column 3 
represents the percent of total opioid analgesic prescriptions (column 2) that were extended-
release (ER) (n=858,118). The denominator for column 4 is the total number of unique 
recipients of opioid analgesics (n=2,182,374). The denominator for column 5 is the number 
of deaths involving opioid analgesics in a primary or additive role (n=629).  
*Methadone involved in overdose deaths is not differentiated by formulation, and include 
mentions of methadone in tablet form (pain management) as well as liquid (management of 
opioid dependence). 
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Figure 5.4. Incidence rates and incidence rate ratios for overdose deaths 
involving opioid analgesics, by average milligrams of morphine equivalents, 
North Carolina residents, 2010. The incidence rate appears to be distinctly 
elevated at doses greater than 200 mg average daily MME, top graph. Dotted lines 
are the bounds of the 95 percent confidence intervals (CI). In the bottom graph, the 
reference group for incidence rate ratios (IRR) is >0 to 19.9 mg of average daily 
milligrams of morphine equivalents, represented by the solid black square. IRRs and 
CIs (dotted lines) were estimated using Poisson regression, with person-days of 
exposure accrued in an intent-to-treat-type manner. The vertical axis in the lower 
graph is plotted on the log10 scale. Average daily MME are plotted at the midpoint of 
the each category range; the last point includes 500 through 5,000 mg/day. 
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Figure 5.5. Mortality rates for overdose involving opioid analgesics, by average 
milligrams of morphine equivalents and formulation type, North Carolina 
Residents, 2010. The IR-only category contains those who had only received IR 
opioid prescriptions in the 365 days prior to death or end of the study, versus those 
who had at least one ER prescription. Reference group for incidence rate ratios 
(IRR) is >0 to 19.9 mg/day of average daily milligrams of morphine equivalents 
(MME). Grey lines are the bounds of the 95 percent confidence interval (CI). IRRs 
and CIs were estimated using Poisson regression, with person-days of exposure 
accrued in an intent-to-treat-type manner. The vertical axis is plotted on the log10 
scale. Average daily MME are plotted at the midpoint of each category range; the 
last point includes 300 through 5,000 mg/day.  
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Figure 5.6. Incidence rate ratios for overdose deaths involving opioid 
analgesics, by average milligrams of morphine equivalents and 
benzodiazepine prescription status, North Carolina Residents, 2010. 
Benzodiazepine exposure was determined by receipt of at least one prescription for 
a benzodiazepine in 365 days prior to death or end of the study, versus those who 
had no record of such a prescription. Reference group for incidence rate ratios (IRR) 
is >0 to 19.9 mg/day of average daily milligrams of morphine equivalents (MME). 
Grey lines are the bounds of the 95 percent confidence interval (CI). IRRs and CIs 
were estimated using Poisson regression, with person-days of exposure accrued in 
an intent-to-treat-type manner. The vertical axis is plotted on the log10 scale. Average 
daily MME are plotted at the midpoint of the each category range; the last point 
includes 500 through 5,000 mg/day. 
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CHAPTER 6 
SYNTHESIS 
Overview  
 The scope of Aim 1 was to evaluate between seven ICD-10-based definitions of 
opioid overdose mortality from North Carolina vital statistics. We evaluated the impact of 
including substance use disorders and pharmaceutical adverse events codes in 
definitions of overdose. Our suggestion is to include deaths attributable to substance 
abuse, but not pharmaceutical adverse events where controlled substances are not 
mentioned. We also proposed a definition for use in surveillance based on the findings. 
 The scope of Aim 2 was to conduct a prospective cohort study using mortality 
data linked to opioid analgesic dispensing data to examine the association between 
dose and overdose risk. First, we described patterns of clinical opioid analgesic 
utilization, focusing on prescribers, prescriptions, and patients, with attention to opioid 
substance and formulation type. Second, we examined the relationship between high 
dose opioid analgesic prescribing and overdose mortality, and confirmed the findings of 
previous studies. Third, we evaluated the differences between high doses of IR and ER 
opioid analgesics on overdose mortality, and how this relationship may be influenced by 
benzodiazepine co-prescribing. We found that overdose risk increases with MME dose, 
as expected, increasing substantially after 200 mg average daily MME. We also found 
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that benzodiazepine prescription significantly increased the risk of overdose, especially 
at high doses. 
Major Findings 
 The major findings from Aim 1 (first manuscript) were as follows: 
• Deaths resulting from adverse events involving non-controlled substances are 
included in routinely used ICD-10-based definitions of “drug overdose.” While 
adverse events involving controlled and unknown substances could benefit from 
inclusion in overdose definitions, deaths explicitly involving non-controlled 
substances should be analyzed separately. 
• Deaths resulting from substance use disorders are included in some, but not all, 
definitions of overdose. These deaths are likely to be of interest in surveillance 
and would benefit from inclusion in overdose definitions. 
• Controlled-substance toxicology codes are mentioned as contributing causes-of-
death among death records with non-poisoning and non-substance abuse 
underlying cause-of-death. These deaths are likely to be of interest in 
surveillance and would benefit from inclusion in overdose definitions. 
 The major findings from Aim 2 (second manuscript) were as follows: 
• Annually, 22.8% of North Carolina residents are dispensed opioid analgesics, 
and nearly all licensed clinicians prescribe them. 
• Risk of overdose increased continuously with MME, but no threshold dose was 
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found corresponding to a notable inflection. 
• At lower doses (less than 100 mg/day MME), for every 2,003 patients treated for 
a year with ER opioid analgesics instead of IR, there would be one additional 
overdose death. At higher doses, there would be one additional overdose death 
for approximately every 1,300 patients treated for a year with ER instead of IR 
opioid analgesics. 
• Benzodiazepine prescription status substantially modified the risk of overdose at 
higher doses of opioid analgesics. Since 80% of opioid analgesic patients also 
received benzodiazepines, overdose risk during routine clinical practice may be 
largely different from the controlled settings of clinical trials. 
Limitations 
 Four major limitations from this work are summarized here. First, the most 
serious limitation is inherent to the design of observational studies and pertains to the 
second paper. There is a fundamental question of exchangeability when comparing 
patients at different doses of the same medication. Patients receiving higher doses could 
potentially be more likely to have serious illnesses (e.g., cancer pain) and co-morbid 
conditions, relative to those receiving opioids for acute and less severe and transient 
conditions (e.g., routine dental procedures). As such, the risk of respiratory distress or 
depression may be different at the point of starting therapy. In addition, there is likely to 
be more careful patient selection and monitoring by the physician for patients with 
severe chronic pain conditions that may be receiving opioids. For example, more 
frequent follow-up visits, urine toxicology screens, and other tools may be used 
preferentially among high-dose patients, resulting in decreased risk for overdose. We did 
not have access to these treatment decision-related covariates, and it is unlikely that 
such data would be available for all 22.8% of NC residents who received opioid 
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analgesics.  
 The second major limitation is that we did not take into account time on therapy 
in our models.  Like the first major limitation, this is mainly pertinent to the second paper. 
We dichotomized person-time as either exposed to therapy or not, similar to the 
approach taken by others [13,14,15,16,17]. The first weeks of starting opioid therapy 
may pose the greatest risk for overdose, and that overdose risk declines as tolerance 
increases and plasma concentration reaches steady state. We could examine this 
hypothesis with a new user design and looking at time to death, and this will be the 
subject of future analyses. 
 A third limitation applies to both papers, and all studies of overdose mortality 
using vital statistics. Medical examiners are required to investigate suspicious and 
unnatural deaths, however, we have limited information on deaths that should have been 
considered an overdose but were not observed because an autopsy was not performed. 
In general these are forms of outcome identification bias or diagnostic suspicion bias 
where the outcome is more likely to be investigated because exposure is suspected. The 
underlying cause-of-death may be marked as a non-poisoning and non-substance abuse 
code. Of note, there were 36 additional deaths per year on average where controlled-
substances toxicology codes were present. However, stigma associated with overdose 
and life insurance benefit considerations may also influence those certifying the death to 
leave out mention of substance abuse or overdose, in favor of less stigmatized 
respiratory depression or cardiac arrest mentions. We anticipate that the effect of this 
bias is likely to be small. 
 A fourth limitation concerns the data source for prescription data. Dispensing 
data from PMPs, while relatively new and potentially important, have not been used 
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extensively in research. There may be unanticipated limitations that are not apparent at 
this time. The analyses are necessarily dependent on reliable identification of unique 
patients, an assumption we cannot test within the data we have access to. We are 
encouraged that others have noted similar prevalence of utilization of opioid analgesics 
from other commercial and national sources [104], using data from a different source 
likely to de-duplicate patients using a different proprietary algorithm. Collaboration with 
the data vendor and matching of PMP records to prescription benefits claims data could 
be one way to examine the reliability of de-duplication algorithms. 
Strengths 
 Overdose numbers issued by state and national governments are dependent on 
quantification of vital statistics data based on ICD-10 coding. As others have suspected 
[70,71], and we were able to confirm, there are many opportunities for misclassification 
of deaths. However, there have been very few studies dissecting the implications of 
using particular ICD-10 codes for surveillance. Aim 1 (first manuscript) is one of the most 
detailed examinations of ICD-10 coding of overdose deaths conducted to date.  
 Aim 2 (the second manuscript) is the largest cohort study to date examining the 
association between high-dose opioid analgesic utilization and overdose risk. This 
analysis has more than three times as many exposed patients as the next largest study. 
The large sample size allowed us to estimate dose-specific risks of overdose for a more 
nuanced gradient of opioid analgesic doses than previous studies, including a dose 
range routinely used in clinical practice. The analysis is also one of the first to use PMP 
data for epidemiologic research. The proliferation of these and other electronic 
prescription databases has opened up an opportunity for drug safety research, but they 
are limited in that they do not include outcome data. Fortunately, the North Carolina 
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Division of Public Health had recently conducted a painstaking matching of PMP records 
to medical examiner data. By conceptualizing this Aim as a statewide cohort study, we 
were able to combine this large-scale chart review with the statewide prescription 
database. This methodology has not been previously applied to the study of prescription 
drug overdose deaths.  
Public Health and Policy Impact 
 The two Aims presented here have distinct audiences and applications. As a 
definitional study, the first investigation is likely to be of interest to injury surveillance 
epidemiologists at the state and national level, in particular to ISW, CSTE, ASTHO, and 
CDC. Ultimately we hope that the analyses may inform future revisions to ICD to clarify 
and help consolidate some of the disparate sets of codes that can be used for overdose. 
We observed that up to 16.1% of purported overdose deaths might be adverse events 
unrelated to controlled substances. This has implications for incidence estimates, 
government and foundation funding priorities, and intervention evaluation. The 
evaluation of interventions tailored specifically at preventing controlled substance 
overdose, such as the long-acting and extended-release opioid REMS, will be hard to 
evaluate if the non-controlled substance adverse events are included. Assuming no 
change in the methods of measurement over time, these extra decedents could be 
conceptualized as being immune to the intervention and their inclusion may decrease 
the apparent impact of any intervention.  
 The implications of Aim 2 are relevant to clinical decision-making. Our data 
indicate that 132,732 patients in North Carolina received doses of opioid analgesics 
greater than 100 average daily MME in 2010, and this level can be reached by a single 
tablet or patch of many ER opioid analgesics. There is clearly a place for high-dose 
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opioid formulations in modern medicine. However, previous research provided little 
insight on risks above 100 MME by treating higher doses all the same. Aim 2 is the first 
study to describe the shape of the curve of overdose risk above 200 mg. We hope that 
our work will facilitate more nuanced clinical decisions about dose escalation. 
 There are possible policy implications from Aim 2. While the FDA has chosen to 
focus on long-acting and extended-release opioids, it is clear that immediate-release 
opioids are also prescribed in a manner that raises concerns. The Aim 2 analysis is 
among the first to document off-label use of high-dose opioids. The FDA has required 
REMS to limit off-label use of transmucosal immediate-release fentanyl products, and it 
is reasonable to expect that other IR opioids may warrant REMS as well. However, most 
IR opioid analgesics are made by generic manufacturers who have traditionally been 
exempted or given lesser REMS requirements than innovator products. Our Aim 2 
results suggest that a comprehensive approach to all opioid analgesics is needed.  
 There is policy pressure on FDA from advocacy groups to limit the doses of 
opioid analgesics through label changes. One example is the Physicians for Responsible 
Opioid Prescribing (PROP) which has petitioned the Agency to “Add a maximum daily 
dose, equivalent to 100 milligrams of morphine for non-cancer pain” [109], which the 
DEA and CDC have endorsed as well. The petition cites three of the other individual-
level studies on this topic [13,14,16], but does not justify why 100 milligrams should be a 
cut-off. While we do not address the question of cancer versus non-cancer pain, our 
study does provide the first published examination of the gradient of risk at higher MME. 
We hope that Chapter 5 will contribute to the informed debate on what are safe 
thresholds for opioid prescribing. 
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 Concerns about inadequately managed pain in chronic pain patients are credible, 
yet publications about overdose statistics tend to only include data on the negative 
consequences of opioid availability. Injury prevention research and the clinical practice 
of pain management are relatively separated in the scientific literature. In the spirit of 
trying to create collaborative linkages, we made efforts to include a measure of access 
to care in our analysis of opioid analgesic dose and mortality. By including data from 
licensing authorities, we were able to compute the percent of providers who prescribe 
each type of opioid analgesic, and estimate the prevalence of off-label use. This type of 
information is important because it provides scope for future intervention design, e.g., a 
meaningful sense of the magnitude of medical education for opioid prescribers. 
 
 
Directions for Future Research 
 The studies presented here naturally suggest avenues for further exploration. 
Below we list some of the possible avenues of further research. 
• New user design: To understand the time-varying risk of overdose, we propose 
to study only those patients who are new to opioid therapy, using data from the 
CSRS. A suitable washout period would have to precede eligibility. Patients 
could be followed forward in time to overdose endpoint using modeling 
techniques such as proportional hazards regression. 
• Understanding why patients receive off-label high-dose and long-term IR opioid 
analgesics: Clinical insight, chart review, and qualitative information from patients 
would be required to generate hypotheses. Based on these findings, electronic 
medical records, and possibly claims data, could be useful to understand opioid 
prescribing preferences. Models could be developed that account for propensity 
to be prescribed certain types of opioids based on underlying medical 
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comorbidities. 
• Investigation of non-fatal overdose: Non-fatal overdoses are observed during 
interactions with the medical system in hospital emergency departments, poison 
centers and through pre-hospital emergency medical services. Surveys of drug 
users are also important sources of information on overdose survivorship. Few 
analytic studies have been conducted with non-fatal overdose. Data quality 
assessment (e.g., ICD coding consistency in hospital emergency department 
data) is required as a first step, possibly through matching data from surveillance 
systems with chart review. If data are deemed to be of acceptable quality, similar 
dose-dependent modeling of opioid analgesic use and non-fatal overdose as 
paper two could be envisioned. 
• Consistency in medical examiner determination of death: Medical examiner data 
for overdose mortality are the cornerstone of vital statistics-based surveillance in 
this field. However, the impact of medical examiner operating procedures on 
epidemiologic outcomes for overdose mortality have not been fully elaborated. 
For example, we have limited understanding how primary and additive are 
assigned to substances detected in post-mortem toxicology, and how this may 
influence the results of our study. Research methodology in this area would have 
to be developed in close conjunction with medical examiner officials. 
• Cancer vs. non-cancer pain: There are major policy questions about the use of 
opioid analgesics for long-term non-cancer pain. While the data we had did not 
allow us to explore this dimension, using electronic data from academic hospitals 
or public assistance drug benefit programs might allow us to align clinical 
diagnoses with prescriptions and overdose. 
• Access to care: We have provided initial direction for a population-level access to 
care measure: the percent of licensed prescribers within a state writing 
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prescriptions for ER opioid analgesics. Methods for estimating serious pain 
prevalence have evolved. A telephone stratified probability sample of 5,357 North 
Carolina households revealed that approximately 10% of respondents suffered 
from chronic disabling back pain [101]. Combining data from surveys with 
electronic prescription records could allow for more nuanced population-level 
measures of access to care.  
• Framework for intervention evaluation: Continuing from the previous bullet, 
access to care measures could be used in combination with prescribing patterns 
and overdose mortality or morbidity data to provide a comprehensive framework 
for evaluation of interventions intended to reduce overdose involving opioid 
analgesics, in North Carolina and beyond. 
 Overdose death involving prescription opioids is a major public health problem in 
the United States. The first part of this dissertation informs the methodology for 
calculating the prevalence of overdose deaths using vital statistics. The second part of 
this dissertation provides detailed information on the dose-response between opioid 
analgesics and overdose risk. We hope our investigations will inform epidemiology and 
clinical decision-making related to this important topic. 
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APPENDIX 1. ANALYSIS OF NARCOTIC UNSPECIFIED DEATHS  
 Only 62 (1.3%) death records out of 4,635 overdoses had a “narcotic 
unspecified” code in the contributing cause-of-death fields, with 27 containing no other 
specified toxicology code for a controlled substance.  
 Of the 62 deaths, many had some indication that they were opioid-related. 
Eleven had T codes for a prescription opioid (T40.2, T40.3 or T40.4) and one had a code 
for heroin. There were six deaths with codes for cocaine (T40.5) in conjunction with 
T40.6 (but no T40.0 through T40.4 opioids), with the “unspecified narcotic” code 
suggesting the presence of an opioid. Of the remaining 44 deaths, benzodiazepine 
toxicity (T42.4) was listed in 17 cases; given the known risk of respiratory depression 
between opioids and benzodiazepines, these may be more likely to be deaths involving 
opioids than cocaine. Six deaths had a code for anoxic brain damage (G93.1), which is 
more indicative of opioid poisoning than cocaine toxicity. 
 The remaining 21 deaths are a complicated mix with contributing cause-of-death 
codes that include major depressive disorder, asphyxiation, cardiovascular and 
cerebrovascular disease, alcohol dependence, HIV-related encephalopathy, and chronic 
pain. Examination of the literal text of the cause-of-death fields for 2010 and 2011 
confirmed the findings from ICD-10 coded vital statistics data for deaths with T40.6. 
Multiple drug toxicity (including ethanol and benzodiazepines) was commonly 
mentioned, but deaths involving T40.6 also mentioned the involvement of tapentadol, 
tramadol and propoxyphene, opioids atypically found in overdose deaths in the United 
States, as well as gabapentin. 
 We chose to include T40.6 in the opioid definition at this time because most 
deaths with this code had other indications of the involvement of opioids. This may 
change over time and should be assessed in each state. Only about half of the deaths 
with T40.6 had an autopsy performed, compared with about 80% for overdoses in 
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general. While the magnitude of the potential for misclassification is fairly limited in the 
North Carolina data when used for surveillance purposes, if the research question 
focuses on drug-related deaths in the hospital setting the treatment of T40.6 will have to 
be handled with care to minimize the potential for bias. 
 It should be noted that T40.2 (codeine, morphine, oxycodone, etc.), T40.3 
(methadone), and T40.4 (buprenorphine, fentanyl, propoxyphene, etc.) are intended to 
identify the psychoactive substance involved in the poisoning death, and are not per se 
intended to identify whether they are pharmaceutical preparations. This distinction was 
important during the outbreak of overdose deaths in the United States due to heroin 
adulterated with illicitly manufactured fentanyl [85]. Unless ICD is revised to reflect the 
source or manufacturing method of the opioid, the existing structure of this class of T 
codes will limit long-term and cross-national comparisons since opioids that were 
originally pharmaceuticals may one day become predominantly manufactured illicitly 
(e.g., heroin, methamphetamine) or may have geographically isolated modifications of 
the medicine (e.g., Krokodil) [110]. T codes also do not differentiate methadone tablets 
used in analgesia from liquid methadone used in opioid dependence treatment 
programs, or transdermal buprenorphine used for chronic pain versus sublingual 
buprenorphine formulations used for outpatient management of opioid dependence 
disorders. 
 These results suggest that the majority of these deaths are due to opioid 
poisoning and that T40.6 should be included in definitions of opioid mortality. The 
relative proportion of deaths with a T40.6 code was small, and bias from including this 
code is low at a state level. It appears that the majority of T40.6 deaths are likely to 
involve opioids, including opioids that have incomplete agonism at the mu-opioid 
receptor but can nevertheless contribute to central nervous system depression. It 
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appears to be warranted to retain T40.6 deaths in definitions of opioid overdose for the 
sake of surveillance using vital statistics data in North Carolina.  
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APPENDIX 2. SEASONALITY AMONG OVERDOSE DEATHS 
 Definitions 1, 2, and 3 to the North Carolina data generated three monthly time 
series of overdose deaths that were nearly indistinguishable from each other, and 
opioid-specific Definitions 4, 6, and 7 yielded similar results (data not shown). We 
selected Definition 1 and 4 to represent the broader and more general definitions in 
seasonality analysis. Both sets of definitions showed similar patterns over time, 
suggesting that the drug overdose epidemic in North Carolina was largely driven by 
opioids. When monthly time series were smoothed using LOESS regression, possible 
seasonality may be present with a peak in April, Figure 4.2. For all drug overdoses 
identified using Definition 1, the Walter and Elwood test suggested the presence of 
seasonality (chi-square 8.2, p=0.016, 2 df) with a peak in the middle of April (106.0 
degrees), but with poor fit (chi-square 20.6, p=0.037, 2 df) and not taking into account 
general seasonality of deaths. Taking into account background fluctuations in mortality 
confirmed that seasonality was present (chi-square 17.3, p=0.0002, 2 df), but with a 
peak in early June (158.0 degrees) relative to other deaths, and with reasonable model 
fit (chi-square 15.4, p=0.17, 2 df). For opioid overdoses identified using Definition 4, the 
results were more conclusive. The simple Walter Elwood exact method test suggested 
the possible presence of seasonality (chi-square 5.8, p=0.05, 2 df) with a peak in middle-
to-late March (82.9 degrees) and reasonable model fit (chi-square 17.1, p=0.10, 2 df). 
Seasonality persisted after taking background deaths into account (chi-square 8.8, 
p=0.032, 2 df), with good model fit (chi-square 13.3, p=0.272, 2 df), but reaffirmed that 
the peak was in late May (147.4 degrees) for opioid deaths relative to all other deaths.  
 Despite the suggestion of a small peak in late Spring, we felt that any effect of 
seasonality was relatively minor in these data. As the project shifted from time series 
modeling to causal inference, the importance of seasonality adjustments was 
diminished. 
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